Fragrance composition for improving sleep

Abstract

Provided herein is a fragrance composition comprising a heteroatomic musk compound and / or an acyclic musk compound, which induces improved sleep in a subject upon exposure to the fragrance composition. Also provided are consumer products containing such fragrance compositions and methods of use thereof.

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority from U.S. Provisional Patent Application No. 63 / 316,496, filed March 4, 2022, the contents of which are incorporated by reference in their entirety herein.

[0002] The present disclosure relates to fragrance compositions, and more particularly to musk-containing fragrance compositions that induce improved sleep in a subject upon exposure to the fragrance composition. The present disclosure also relates to consumer products containing such fragrance compositions and methods of use thereof. [Background technology]

[0003] Insufficient sleep and / or poor quality sleep is a modern challenge that negatively impacts health and social productivity worldwide. It is reported that 84% of the world's population has experienced some form of sleep difficulty. The US CDC (Centers for Disease Control and Prevention) recommends that adults aged 18 and older should get at least 7 hours of sleep per night, as good quality sleep correlates with many benefits, such as better mood, appearance, immune health, and cognitive / physical function (e.g., focus, memory, etc.). Unfortunately, in recent years (especially during the COVID pandemic), there has been a sharp increase in the number of people reporting issues with insufficient sleep and / or poor quality sleep. In fact, a study published in the Harvard Business Review found that lost productivity due to sleep-deprived employees costs four companies a combined US$54 million per year.

[0004] Common ways to address this problem include taking prescription (e.g., zolpidem, sold as Ambien) and / or over-the-counter (OTC) medications (e.g., melatonin supplements). Problems with this solution may include: (i) the real risk of abuse and addiction to the sleep aid Ambien, (ii) harmful side effects, (iii) limited availability of melatonin due to differences in regulatory systems (e.g., melatonin sold OTC in the United States is available only by prescription in other countries), and / or (iv) the tendency of these pharmaceutical solutions to address only specific sleep problems (e.g., Ambien treats insomnia, while melatonin promotes sleep-wake cycles).

[0005] Another approach involves the use of aromatherapy solutions to affect the sleep patterns of consumers. Commonly used scents include lavender, rose, ylang-ylang, geranium, clary sage, neroli, marjoram, etc., which are widely known as essential oils with sedative effects (JP Patent No. 5019016B2, Takasago International Corporation). However, the drawbacks of these natural oils may include: (i) they each have a characteristic / unique scent, but the preferences tend not to be shared among different consumers, which may cause others in the vicinity to feel disgust or irritation, etc., and / or (ii) the essential oils tend to have different effects. U.S. Patent Application Publication No. 2021 / 0008082A1 (Takasago International Corporation) discloses a fragrance composition useful for improving sleep, comprising at least one floral compound and at least one musk compound selected from Ambroxan®, Ambretone®, L-Muscone, Habanolide®, and Musk T®. US 2020 / 0048578 A1 (Givaudan SA) describes a method for preparing a fragrance composition adapted to address sleep quality, the composition containing 0.01-50% by weight of a number of fragrance ingredients, including at least one musk component (B15) selected from ambrette, Cashmeran®, Cosmone®, cyclopentadecanolide, ethylene brassylate, Galaxolide®, Galaxolide S, Habanolide®, muscenone, Musk C14, Serenolide®, Silvanone® Supra, Sylkolide® and Velvione®. These attempts have encouraged the indiscriminate use of such musk compounds without considering the type of musk compound and / or their impact on sleep benefits. Thus, while these attempts disclose the use of musk compounds in fragrance compositions to obtain sleep quality, they do not teach the specific types of musk compounds or the amounts of these types of musk compounds that should be included to provide the benefit of improving the quantity and / or quality of sleep. Summary of the Invention [Problem to be solved by the invention]

[0006] Therefore, there remains a need to identify fragrance compositions that effectively improve the quantity and / or quality of sleep of individuals, particularly in a safe, non-pharmacological and / or non-invasive manner.It is desirable to have fragrance compositions that can be used in consumer products to improve the sleep benefits of subjects.The present disclosure addresses these and other needs, as will be disclosed in more detail below. [Means for solving the problem]

[0007] The present invention is based on the discovery that a combination of musk compounds, particularly heteroatomic musk compounds and / or acyclic musk compounds, can be formulated into a fragrance composition (optionally containing MCM and linear musk compounds and / or additional heteroatomic musk compounds) that improves sleep in a subject, and preferably enhances at least one sleep benefit. It has also been found that compounds with specific backbone structures are useful for improving sleep. For example, compounds containing such backbones can improve one or more of the sleep benefits. Such compounds can be formulated into a fragrance composition that improves sleep. Furthermore, the fragrance compositions of the present disclosure have been shown to improve sleep benefits in a novel olfactory direction (i.e., away from traditional lavender), have no adverse effects, and / or have high consumer acceptability when used alone or as part of a total sleep solution, for example, sprayed on a pillowcase as a nightly routine.

[0008] In one embodiment, the backbone structure of formula (I): [ka] wherein each open position of the backbone structure is independently optionally substituted; [ka] is a single bond or a double bond; and the six-membered ring of formula (I) has 0 to 3 double bonds. wherein the one or more compounds having the backbone structure of formula (I) are present in a total concentration of greater than 0.05 wt. % of the total weight of the composition.

[0009] In one aspect, there is provided a fragrance composition for improving sleep comprising one or more heteroatomic musk compounds, wherein the one or more heteroatomic musk compounds are present in a total concentration greater than 0.05 wt. % of the total weight of the composition.

[0010] In one embodiment, a fragrance composition for improving sleep is provided, comprising at least four fragrance ingredients, including (i) at least three heteroatom musk compounds; and (ii) at least one acyclic musk compound, 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline or 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole. In one embodiment, a fragrance composition for improving sleep is provided, comprising at least four fragrance ingredients, including (i) at least three heteroatom musk compounds; and (ii) at least one acyclic musk compound or 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline. The fragrance composition optionally comprises a solvent selected from dipropylene glycol (DPG), isopropyl myristate, ethanol, triethyl citrate, or combinations thereof.

[0011] In another aspect, the present disclosure relates to a consumer product comprising the fragrance composition described herein, the consumer product being an air care product, a home care product, a personal care product, a hygiene product, a pet care product, a fine fragrance, a hair care product, or a beauty care product. In one aspect, the present disclosure relates to a consumer product comprising the fragrance composition described herein, the consumer product being an air care product, a home care product, a fabric care product, a personal care product, a hygiene product, a pet care product, a fine fragrance, a hair care product, or a beauty care product. In a particular embodiment, the present disclosure relates to an air care product, the release of the fragrance composition is triggered biometrically, preferably by a consumer biometric reading. In some embodiments, the air care product containing the fragrance composition releases the fragrance composition in response to a biometric reading, for example, a consumer biometric reading. In this way, for example, the release of the fragrance composition is triggered by biometric data.

[0012] In yet another aspect, the present disclosure relates to a method of improving at least one sleep effect in a subject, comprising providing a fragrance composition as described herein or a consumer product as described herein to the subject in an amount effective to improve at least one sleep effect. Preferably, the fragrance composition or consumer product is (i) sprayed or applied to the subject; (ii) sprayed or applied to furniture upholstery or fabrics, preferably bedding, laundry, blankets or pillowcases; and / or (iii) dispersed or diffused in the air.

[0013] Therefore, advantageously, the present disclosure provides novel design guidelines for formulating fragrance compositions intended to improve sleep. In particular, the design guidelines identify selected musk compounds intended to be incorporated into fragrance compositions for the purpose of providing one or more sleep benefits to a subject in need thereof by administering a fragrance composition disclosed herein in an amount effective to provide one or more sleep benefits to the subject in need thereof. In embodiments, the design guidelines identify compounds having the framework structures described herein for the purpose of providing a fragrance composition for the purpose of providing one or more sleep benefits to a subject in need thereof by administering a fragrance composition disclosed herein in an amount effective to provide one or more sleep benefits to the subject in need thereof. Yet another advantage is the ability to create novel fragrance profiles that improve sleep.

[0014] All parts, percentages and ratios referred to in the specification and claims are by weight unless otherwise stated.

[0015] Values ​​and dimensions disclosed herein should not be understood as being strictly limited to the exact numerical values ​​recited. Instead, unless otherwise specified, each such value is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a value disclosed as "50%" is intended to mean "about 50%" or alternatively, for example, about ±2%, ±5%, ±10%, or ±15% of that value.

[0016] In the following description, one or more aspects of the present disclosure will be described in detail. Each of the aspects and embodiments described herein can be used together unless expressly or explicitly excluded in relation to that embodiment or aspect. Other features, objects and advantages of the present disclosure will be apparent to those skilled in the art from the detailed description and drawings.

[0017] While the specification concludes with claims particularly specifying and distinctly claiming the invention, it is believed the present invention will be more fully understood from the following description of the accompanying drawings. [Brief description of the drawings]

[0018] [Figure 1] 1 shows a timetable of the general design of the sleep monitoring study described in Example 2.

[0019] [Diagram 2] 1 shows the pre-sleep questionnaire completed just before bedtime by participants in the study described in Example 2.

[0020] [Diagram 3] FIG. 1 shows the morning questionnaire that participants in the study described in Example 2 completed after they were fully awake.

[0021] [Figure 4A-B] 1 shows a product usage questionnaire that participants completed based on their experience with the product they used the night before the study described in Example 2.

[0022] [Diagram 5] 1 shows a timetable of the general design of the sleep monitoring study described in Example 4. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0023] definition As used herein, articles such as "a" and "an," when used in the claims, are understood to mean one or more of what is claimed or described.

[0024] As used herein, the terms "comprising", "including" and "comprising" are synonymous with "including", "comprises" or "containing", "containing" and grammatical variations thereof and are inclusive or open-ended and do not exclude additional, unrecited elements, components or method steps. The terms "comprising", "comprising" and "comprising", "comprising", "comprises" or "containing", "containing" and grammatical variations thereof also encompass the term "consisting of".

[0025] The term "acyclic musk compounds" (ACMs) as used herein refers to a class of synthetic musk compounds consisting of a single ring composed of six or fewer carbons. A non-limiting example of an acyclic musk compound is Helvimor (i.e., Helvetolide®).

[0026] The term "administration" as used herein refers to introducing or delivering a fragrance composition or fragrance compound to a subject to perform its intended function (e.g., sleep aid). Administration may be by inhaling, sniffing, and / or inhaling. Administering or administration includes self-administration and administration by another. In some embodiments, administration may be performed by a device, such as a smart device.

[0027] As used herein, the term "bedtime" refers to the time when a subject normally goes to bed to sleep.

[0028] As used herein, the term "biometric or biosensed" refers to a statistically validated, rigorously conducted, real-world sleep study designed and approved by sleep experts to measure sleep outcomes based on biometric or self-reported assessments.

[0029] As used herein, the term "deep sleep" refers to stage N3 and / or stage N4 sleep, i.e., when the body is less responsive to external stimuli, breathing slows, muscles relax, and the heart rate becomes more regular. Deep sleep is reported both as the absolute time in minutes spent in deep sleep and as the percentage of total sleep time spent in deep sleep (on a scale of 0 to 100).

[0030] The term "fragrance composition" as used herein refers to a mixture containing one or more fragrance compounds for improving sleep benefits. In some embodiments, the fragrance composition consists solely of fragrance compounds for improving sleep benefits. In other embodiments, the fragrance composition comprises fragrance compounds for improving sleep benefits and one or more other fragrance compounds, preferably intended to impart an olfactory characteristic.

[0031] As used herein, the terms "perfume material", "perfume ingredient" and "perfume compound" are used interchangeably and refer to a perfume raw material ("PRM") or a mixture of perfume raw materials ("PRMs") that are used to impart an overall pleasant odor or perfume profile to a composition. A "perfume material" may include any perfume raw material suitable for perfumery applications, including, for example, materials such as alcohols, aldehydes, ketones, esters, ethers, acetates, nitriles, terpene hydrocarbons, nitrogen- or sulfur-containing heterocyclic compounds and essential oils. However, natural plant and animal oils and exudates containing complex mixtures of various chemical components are also known to be used as "perfume materials". Individual perfume raw materials, including known natural oils, can be found by consulting journals such as "Perfume and Flavourist" or "Journal of Essential Oil Research" that are commonly used by those skilled in the art, or can be found in reference books such as the book S. Arctander, Perfume and Flavor Chemicals, 1969, Montclair, New Jersey, USA, recently reprinted in 1994 by Allured Publishing Corporation Illinois. In addition, some perfume raw materials are provided by fragrance houses (Firmenich, International Flavors & Fragrances, Givaudan, Symrise) in the form of mixtures with their own special accords. Non-limiting examples of perfume materials useful herein include pro-perfumes, such as acetal pro-perfumes, ketal pro-perfumes, ester pro-perfumes, hydrolyzable inorganic-organic pro-perfumes, and mixtures thereof. Perfume materials can be released from pro-perfumes in many ways. For example, the perfume may be released as a result of simple hydrolysis, or by a shift in an equilibrium reaction, or by a pH change, or by enzymatic release.

[0032] As used herein, "increase" with respect to sleep effect means a change in a favorable direction of at least about 0.05%, including, but not limited to, a change in a favorable direction of about 0.05%, about 0.5%, about 1%, about 2%, about 5%, about 10%, about 25%, about 30%, about 50%, about 75% or about 100%.

[0033] As used herein, the term "light sleep" refers to stage N1 and / or stage N2 sleep, during which the individual becomes less aware of their surroundings, their body temperature drops, and their breathing and heart rate become more regular. Light sleep is reported both as the absolute time in minutes spent in light sleep and as the percentage of total sleep time spent in light sleep (on a scale of 0 to 100).

[0034] The term "macrocyclic musk compounds" (MCMs) as used herein refers to a class of synthetic musk compounds consisting of a single ring made up of more than six carbons (often 10-15 carbons). Non-limiting examples of macrocyclic musk compounds include Ambretone®, ambrettolide, Cosmone®, cyclopentadecanolide, ethylene brassylate, Habanolide®, L-muscone, muscenone, Musk C14, Musk T®, Silvanone® Supra, and Velvione®.

[0035] The term "heteroatomic musk compounds" (HMCs) as used herein refers to a class of synthetic musk compounds consisting of two or more rings containing carbon atoms and / or heteroatoms (e.g., N, O). Non-limiting examples of heteroatomic musk compounds include Ambertonic™, Cashmeran® and Nebulone.

[0036] As used herein, "reduction" with respect to sleep effect means a reduction of at least about 0.05% and equivalent terms, including, but not limited to, a decrease of about 0.05%, about 0.5%, about 1%, about 2%, about 5%, about 10%, about 25%, about 30%, about 50%, about 75% or about 100%.

[0037] As used herein, the term "REM sleep" refers to rapid eye movement (REM) sleep, the stage during which dreaming is most likely to occur. During REM sleep, muscles (other than the eye and respiratory muscles) are actively inhibited from motor function, heart rate increases, and breathing becomes more irregular. REM sleep is reported both as the absolute time in minutes spent in REM sleep and as the percentage of total sleep time spent in REM sleep (on a scale of 0 to 100).

[0038] The term "sleep benefit" as used herein refers to one or more of the following: (1) improved biometric or biosensed sleep quality; (2) increased total sleep time; (3) decreased wake after sleep onset (WASO); (4) decreased %Wake after sleep onset; (5) increased deep sleep (N3 / N4) time; (6) increased % of time spent in deep sleep (N3 / N4); (7) increased REM sleep time; (8) decreased % of time spent in REM sleep. (9) increased duration of light sleep (N1 / N2); (10) increased percentage of time spent in light sleep (N1 / N2); (11) increased sleep efficiency; (12) increased sleep maintenance; (13) decreased number of sleep awakenings; (14) decreased time to fall asleep; (15) increased feeling of restedness; (15) increased feeling of refreshment upon and / or after awakening; (16) increased feeling of recovery; (17) increased feeling of being ready for the day's activities; and (18) decreased daytime sleepiness. Preferably, the sleep benefits are bio-measured or bio-sensed.

[0039] As used herein, the term "sleep efficiency" refers to the percentage of time spent asleep in bed during the night. Sleep efficiency is calculated according to the following formula and reported on a scale of 0 to 100:

number

[0040] As used herein, the term "sleep maintenance" refers to the length or percentage of time spent asleep in bed during the night, which is the time in bed minus the time to fall asleep. Sleep maintenance is reported on a scale of 0 to 100.

[0041] As used herein, the term "sleep onset latency" refers to the time it takes to fall asleep, sometimes simply referred to as sleep onset.

[0042] As used herein, the term "sleep quality" refers to a participant's response in a sleep study. Participants self-report their sleep quality daily on a questionnaire using a Likert scale of 1 to 10.

[0043] The term "subject" as used herein refers to the user of the fragrance composition (or fragrance compound) and / or the intended recipient of the fragrance composition (or fragrance compound) when administered by another person. The term "subject" refers to a human or non-human subject. Non-limiting examples of non-human subjects include non-human primates, dogs, cats, mice, rats, guinea pigs, rabbits, pigs, poultry, horses, cows, goats, sheep, cetaceans, etc.

[0044] As used herein, the term "substantially free" with respect to a substance means that the indicated substance is present in an amount of 0% to about 1% by weight, preferably 0% to about 0.5% by weight, and more preferably 0% to 0.2% by weight. The term "essentially free" means that the indicated substance is present in an amount of 0% to about 0.1% by weight, preferably 0% to about 0.01% by weight, and more preferably is not present at analytically detectable levels.

[0045] As used herein, the term "Wake After Sleep Onset" (WASO) refers to the total time spent awake after initially falling asleep during the night. WASO may also refer to the portion of time spent awake after initially falling asleep during the night (%Wake), which would then be reported as a percentage from 0 to 100.

[0046] As used herein, the terms "g," "mg," and "μg" refer to "grams," "milligrams," and "micrograms," respectively. The terms "L" and "mL" refer to "liters" and "milliliters," respectively.

[0047] As used herein, the terms "include", "includes" and "including" are meant to be open-ended.

[0048] Unless otherwise specified, all percentages are weight / weight percentages. Except for the examples and comparative examples, or unless otherwise expressly indicated, all numbers in this specification indicating the amount of materials or reaction conditions, physical properties and / or uses of materials are understood to be modified by the word "about". Numerical ranges expressed in the form "x to y" are understood to include x and y. For specific features, when multiple preferred ranges are described in the form "x to y", it is understood that any range combining different boundary values ​​is also intended.

[0049] All features disclosed herein may be combined in any combination. Each feature disclosed herein may be replaced by alternative features serving the same, equivalent or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.

[0050] It is understood that the test methods disclosed in the Test Methods section of this application must be used to determine the values ​​of each of the parameters of the invention described and claimed herein.

[0051] fragrance composition

[0052] By working with sleep experts to combine neuroscience, consumer perception and the use of IFF's proprietary artificial intelligence tools to improve the performance of biometric measurements in real environments, the applicant has surprisingly discovered a musk fragrance composition that can improve the quantity and / or quality of sleep and positively improve the lives of consumers suffering from sleep problems around the world. In particular, the applicant has surprisingly discovered that fragrance compositions that follow a set of design guidelines for containing specific types of heteroatomic musk and / or acyclic musk fragrance ingredients are useful for improving at least one or more sleep benefits. Even more surprisingly, the applicants have identified compounds with specific backbone structures that are useful for improving sleep, for example, improving one or more sleep benefits. Thus, in some embodiments, the fragrance composition includes a compound with a backbone structure that is useful for improving one or more sleep benefits. Because the fragrance composition has a pleasant odor profile, the fragrance composition can be easily incorporated into consumer products for a variety of uses.

[0053] In one embodiment, the backbone structure of formula (I): [ka] wherein each open position of the backbone structure is independently optionally substituted; [ka] is a single bond or a double bond; and the six-membered ring of formula (I) contains 0 to 3 double bonds. The present invention provides a fragrance composition comprising one or more compounds having a skeletal structure of formula (I), wherein the one or more compounds having a skeletal structure of formula (I) are present at a total concentration of greater than 0.05% by weight of the total weight of the composition. In some embodiments, each open position of the six-membered ring of the skeletal structure of formula (I) is independently optionally substituted. In some embodiments, the substitution is present only on the six-membered ring. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (I) are substituted. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (I) are unsubstituted. In some embodiments, the one or more compounds having a skeletal structure of formula (I) are present at a total concentration of at least 0.1% by weight of the total weight of the composition.

[0054] In some embodiments, the backbone structure of formula (I) is represented by formula (II): [ka] (pentamethylindane (PMI)) structure. In some embodiments, each open position of the skeletal structure of formula (II) is independently optionally substituted. In some embodiments, all or a portion of the open positions of formula (II) are substituted. In some embodiments, all or a portion of the open positions of formula (II) are unsubstituted. In some embodiments, each open position of the six-membered ring of the skeletal structure of formula (II) is independently optionally substituted. In some embodiments, substitution is present only on the six-membered ring. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (II) are substituted. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (II) are unsubstituted.

[0055] In some embodiments, the backbone structure of formula (I) is represented by formula (III): [ka] (dihydropentamethylindane (DHPMI)) structure. In some embodiments, each open position of the skeletal structure of formula (III) is independently optionally substituted. In some embodiments, all or a portion of the open positions of formula (III) are substituted. In some embodiments, all or a portion of the open positions of formula (III) are unsubstituted. In some embodiments, each open position of the six-membered ring of the skeletal structure of formula (III) is independently optionally substituted. In some embodiments, substitution is present only on the six-membered ring. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (III) are substituted. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (III) are unsubstituted.

[0056] In some embodiments, the backbone structure of formula (I) is represented by formula (IV): [ka] (tetrahydropentamethylindane (THPMI)) structure. In some embodiments, each open position of the skeletal structure of formula (IV) is independently optionally substituted. In some embodiments, all or a portion of the open positions of formula (IV) are substituted. In some embodiments, all or a portion of the open positions of formula (IV) are unsubstituted. In some embodiments, each open position of the six-membered ring of the skeletal structure of formula (IV) is independently optionally substituted. In some embodiments, substitution is present only on the six-membered ring. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (IV) are substituted. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (IV) are unsubstituted.

[0057] In some embodiments, the backbone structure of formula (I) is represented by formula (V): [ka] (Hexahydropentamethylindane (HHPMI)). In some embodiments, each open position of the backbone structure of formula (V) is independently optionally substituted. In some embodiments, all or a portion of the open positions of formula (V) are substituted. In some embodiments, all or a portion of the open positions of formula (V) are unsubstituted. In some embodiments, each open position of the six-membered ring of the backbone structure of formula (V) is independently optionally substituted. In some embodiments, substitution is present only on the six-membered ring. In some embodiments, all or a portion of the open positions of the six-membered ring of the backbone structure of formula (V) are substituted. In some embodiments, all or a portion of the open positions of the six-membered ring of the backbone structure of formula (V) are unsubstituted.

[0058] In some embodiments, when there is more than one compound having a skeletal structure of formula (I) in a fragrance composition, the one or more compounds having a skeletal structure of formula (I) in the fragrance composition have the same skeletal structure of formula (I). For example, in some cases, each compound having a skeletal structure of formula (I) in a fragrance composition has one skeletal structure of formula (II), (III), (IV) or (V). In some embodiments, when there is more than one compound having a skeletal structure of formula (I) in a fragrance composition, the compounds have different skeletal structures. For example, in some cases, the two or more compounds each have different skeletal structures of formula (I), such as two or more of formula (II), (III), (IV) or (V). Any mixture of compounds having the same or different skeletal structures of formula (I) is contemplated herein.

[0059] In some embodiments, at least one of the one or more compounds having the skeletal structure of formula (I) is a heteroatom musk compound. For example, in some embodiments, the compound having the skeletal structure of formula (I) is substituted at an open position, and the substitution is or includes a heteroatom. In some embodiments, the compound having the skeletal structure of formula (I) is substituted at an open position of a six-membered ring, and the substitution is or includes a heteroatom. In some embodiments, the heteroatom is oxygen or nitrogen. In some embodiments, the heteroatom is oxygen. In some embodiments, the heteroatom is nitrogen.

[0060] In some embodiments, the fragrance composition comprises at least 2, 3, 4, or 5 compounds having the skeletal structure of formula (I). In some embodiments, the fragrance composition comprises at least 3 compounds having the skeletal structure of formula (I). In some embodiments, the fragrance composition comprises at least 4 compounds having the skeletal structure of formula (I).

[0061] In some embodiments, the one or more compounds having the backbone structure of formula (I) are selected from the group consisting of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene; 2,2,6,6,7,8,8-heptamethyldecahydro-2H-indeno[4,5-b]furan; 2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more compounds having the backbone structure of formula (I) are selected from the group consisting of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-pentamethyl-6,7,8, 9-tetrahydro-5H-cyclopenta[h]quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene; 2,2,6,6,7,8,8-heptamethyldecahydro-2H-indeno[4,5-b]furan; or one or more stereoisomers of any of the foregoing.In some embodiments, the one or more compounds having the backbone structure of formula (I) are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7 , 7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more compounds having the backbone structure of formula (I) are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl -2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; or one or more stereoisomers of any of the foregoing.In some embodiments, the one or more compounds having the backbone structure of formula (I) are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more compounds having the backbone structure of formula (I) are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more compounds having the backbone structure of formula (I) are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more compounds having the backbone structure of formula (I) include 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline (Ambertonic™) and / or stereoisomers thereof. In some embodiments, the one or more compounds having the backbone structure of formula (I) include indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl (Nebulone®) and / or stereoisomers thereof.In some embodiments, the one or more compounds having the backbone structure of formula (I) include 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one (Cashmeran®) and / or a stereoisomer thereof. In some embodiments, the one or more compounds having the backbone structure of formula (I) include 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline (Sinfonide®) and / or a stereoisomer thereof. In some embodiments, the one or more compounds having the backbone structure of formula (I) include 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole (Operanide®) and / or a stereoisomer thereof. In some embodiments, the one or more compounds having the backbone structure of formula (I) include 4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene (Galaxolide®) and / or a stereoisomer thereof. In some embodiments, the one or more compounds having the backbone structure of formula (I) include 2,2,6,6,7,8,8-heptamethyldecahydro-2H-indeno[4,5-b]furan (Amber Xtreme™) and / or a stereoisomer thereof. In some embodiments, the one or more compounds having the backbone structure of formula (I) include 2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan (TrisAmber™) and / or a stereoisomer thereof.

[0062] In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration of at least about 0.15, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90% or more by weight or 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration of at least about 0.15% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration of at least about 0.2% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration of at least about 0.3% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) at a total concentration of at least about 0.4% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) at a total concentration of at least about 0.5% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) at a total concentration of at least about 1% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) at a total concentration of at least about 10% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) at a total concentration of at least about 40% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) at a total concentration of at least about 50% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration of at least about 75% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration of at least about 90% or more by weight of the total weight of the composition.

[0063] In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.5% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 1% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 5% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 10% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 25% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 50% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 75% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 90% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 95% to about 100% by weight of the total weight of the composition.

[0064] In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 95% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 90% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 75% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 50% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 25% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 10% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 5% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 1% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more compounds having a skeletal structure of formula (I) in a total concentration ranging from about 0.1% to about 0.5% by weight of the total weight of the composition.

[0065] In one aspect, a fragrance composition for improving sleep is provided, comprising one or more heteroatom musk compounds, wherein the one or more heteroatom musk compounds are present at a total concentration of greater than 0.05% by weight of the total weight of the composition. In some embodiments, the one or more heteroatom musk compounds are present at a total concentration of at least 0.1% by weight of the total weight of the composition. In some embodiments, the heteroatom is oxygen. In some embodiments, the heteroatom is nitrogen. In some embodiments, the fragrance composition comprises at least 2, 3, 4, or 5 heteroatom musk compounds. In some embodiments, the fragrance composition comprises at least 3 heteroatom musk compounds. In some embodiments, the fragrance composition comprises at least 4 heteroatom musk compounds.

[0066] In some embodiments, at least one of the one or more heteroatom musk compounds comprises a backbone structure of formula (I) described above, wherein each open position of the backbone structure is independently optionally substituted; [ka] is a single bond or a double bond; and the six-membered ring of formula (I) contains 0 to 3 double bonds. In some embodiments, the open positions of the six-membered ring of the skeletal structure of formula (I) are independently and optionally substituted. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (I) are substituted. In some embodiments, all or a portion of the open positions of the six-membered ring of the skeletal structure of formula (I) are unsubstituted. In some embodiments, the skeletal structure of formula (I) is any one of formula (II) (PMI), formula (III) (DHPMI), formula (IV) (THPMI), or formula (V) (HHPMI), such as those described above. In some embodiments, at least 2, 3, 4, or 5 of the one or more heteroatomic musk compounds have the skeletal structure of formula (I). In some embodiments, at least three heteroatomic musk compounds have the skeletal structure of formula (I). In some embodiments, the at least four heteroatom musk compound has the backbone structure of formula (I).

[0067] In some embodiments, the one or more heteroatom musk compounds are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine; 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline. phosphorus; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene; 2,2,6,6,7,8,8-heptamethyldecahydro-2H-indeno[4,5-b]furan; 2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more heteroatom musk compounds are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine; 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydroinden-4-one; tetrahydro-5H-cyclopenta[h]quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene; 2,2,6,6,7,8,8-heptamethyldecahydro-2H-indeno[4,5-b]furan; or one or more stereoisomers of any of the foregoing.In some embodiments, the one or more heteroatom musk compounds are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7, 8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more heteroatom musk compounds are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine; 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2 , 5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; or one or more stereoisomers of any of the foregoing.In some embodiments, the one or more heteroatom musk compounds are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more heteroatom musk compounds are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more heteroatom musk compounds are 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; or one or more stereoisomers of any of the foregoing. In some embodiments, the one or more heteroatom musk compounds include 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline and / or stereoisomers thereof. In some embodiments, the one or more heteroatom musk compounds include indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl and / or stereoisomers thereof. In some embodiments, the one or more heteroatom musk compounds include 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one and / or stereoisomers thereof.In some embodiments, the one or more heteroatom musk compounds include 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline and / or stereoisomers thereof. In some embodiments, the one or more heteroatom musk compounds include 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole and / or stereoisomers thereof. In some embodiments, the one or more heteroatom musk compounds include 4,6,6,7,8,8-hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene and / or stereoisomers thereof. In some embodiments, the one or more heteroatom musk compounds include 2,2,6,6,7,8,8-heptamethyldecahydro-2H-indeno[4,5-b]furan and / or stereoisomers thereof. In some embodiments, the one or more heteroatom musk compounds include 2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan and / or stereoisomers thereof.

[0068] In some embodiments, the fragrance composition comprises one or more heteroatom musk compounds in a total concentration of at least about 0.15, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatom musk compounds in a total concentration of at least about 0.15% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatom musk compounds in a total concentration of at least about 0.2% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatom musk compounds in a total concentration of at least about 0.3% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatom musk compounds in a total concentration of at least about 0.4% or more by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds at a total concentration of at least about 0.5% by weight or more of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds at a total concentration of at least about 1% by weight or more of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds at a total concentration of at least about 10% by weight or more of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds at a total concentration of at least about 40% by weight or more of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds at a total concentration of at least about 50% by weight or more of the total weight of the composition.

[0069] In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.5% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 1% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 5% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 10% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 25% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 50% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 75% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 90% to about 100% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 95% to about 100% by weight of the total weight of the composition.

[0070] In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 95% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 90% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 75% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 50% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 25% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 10% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 5% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 1% by weight of the total weight of the composition. In some embodiments, the fragrance composition comprises one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 0.5% by weight of the total weight of the composition.

[0071] In some embodiments, the fragrance composition for improving sleep described herein further comprises an acyclic musk compound. In some embodiments, the fragrance composition comprises at least one acyclic musk compound. In some embodiments, the acyclic musk compound is a linear musk compound. In some embodiments, the acyclic musk compound is present at a total concentration of at least or about 0.0025% by weight of the total weight of the composition. In some embodiments, the acyclic musk compound is present at a total concentration of at least or about 0.01% by weight of the total weight of the composition. In some embodiments, the acyclic musk compound is present at a total concentration of at least or about 0.1% by weight of the total weight of the composition. In some embodiments, the acyclic musk compound is present at a total concentration of at least or about 0.5% by weight of the total weight of the composition. In some embodiments, the acyclic musk compound is present at a total concentration of at least or about 1% by weight of the total weight of the composition. In some embodiments, the acyclic musk compound is present at a total concentration of at least or about 5% by weight of the total weight of the composition. In some embodiments, the acyclic musk compounds are present in a total concentration of at least or about 10% by weight of the total weight of the composition. In some embodiments, the acyclic musk compounds are present in a total concentration of at least or about 20% by weight of the total weight of the composition. In some embodiments, the acyclic musk compounds are present in a total concentration of at least or about 30% by weight of the total weight of the composition. In some embodiments, the acyclic musk compounds are present in a total concentration of at least or about 40% by weight of the total weight of the composition. In some embodiments, the acyclic musk compounds are present in a total concentration of at least or about 50% by weight of the total weight of the composition.

[0072] In some embodiments, the acyclic musk is [ka] One or more of the following.

[0073] In some embodiments, the acyclic musk compound is a compound of formula (VI). In some embodiments, the acyclic musk compound is a compound of formula (VII). In some embodiments, the acyclic musk compound is a compound of formula (VIII). In some embodiments, the acyclic musk compound is a compound of formula (IX). In some embodiments, the acyclic musk compound is a compound of formula (X). In some embodiments, the acyclic musk compound is 1-propanol, 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methyl-, 1-propanoate (Helvimor™). In some embodiments, the acyclic musk compound is 1-(3,3-dimethylcyclohexyl)ethyl acetate (Rosamusk™). In some embodiments, the acyclic musk compound is 2-(1-(3,3-dimethylcyclohexyl)ethoxy)-2-oxoethylpropionate (Romanolide®). In some embodiments, the acyclic musk compound is 2-(1-(3,3-dimethylcyclohexyl)ethoxy)-2-methylpropyl cyclopropanecarboxylate (Serenolide®). In some embodiments, the acyclic musk compound is 2-((3,5-dimethylhex-3-en-2-yl)oxy)-2-methylpropyl cyclopropanecarboxylate (Sylkolide®).

[0074] In some embodiments, the acyclic musk compound is present in a weight ratio to one or more of the heteroatom musk compounds. In some embodiments, the acyclic musk compound is present in a weight ratio to one or more compounds comprising the skeletal structure of formula (I). In some embodiments, the weight ratio is about 55:1 to 45:1. In some embodiments, the weight ratio is about 54:1 to 46:1. In some embodiments, the weight ratio is about 53:1 to 46:1. In some embodiments, the weight ratio is about 52:1 to 47:1.

[0075] In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 0.01, 0.02, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 2, 3, 4, 5, 10, 15, or 20% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 0.01% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 0.0125% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 0.015% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 0.02% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 0.25% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 0.05% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 1% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 5% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 10% by weight. In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 15% by weight.In some embodiments, the fragrance composition comprises 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one at a concentration of at least or about 20% by weight.

[0076] In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.01, 0.02, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 5, 10, 20, 30, 40, or 50% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.05% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 1% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 5% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 10% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 20% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 50% by weight.

[0077] In some embodiments, the fragrance composition comprises indeno[4,5-d]-1,3-dioxin,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl at a concentration of at least or about 0.01, 0.02, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 1, 5, 10, 20, 30, 40, or 50% by weight. In some embodiments, the fragrance composition comprises indeno[4,5-d]-1,3-dioxin,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl at a concentration of at least or about 0.05% by weight. In some embodiments, the fragrance composition comprises indeno[4,5-d]-1,3-dioxin,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl at a concentration of at least or about 1% by weight. In some embodiments, the fragrance composition comprises indeno[4,5-d]-1,3-dioxin,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl at a concentration of at least or about 5% by weight. In some embodiments, the fragrance composition comprises indeno[4,5-d]-1,3-dioxin,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl at a concentration of at least or about 10% by weight. In some embodiments, the fragrance composition comprises indeno[4,5-d]-1,3-dioxin,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl at a concentration of at least or about 20% by weight. In some embodiments, the fragrance composition comprises indeno[4,5-d]-1,3-dioxin,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl at a concentration of at least or about 50% by weight.

[0078] In some embodiments, the fragrance composition comprises (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline, and (c) indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl, in a ratio of (a:b:c) ranging from about 1:1.5:1.5 to 1:20:20. In some embodiments, the fragrance composition comprises (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline, and (c) indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl, in a ratio of (a:b:c) ranging from about 1:2:2 to 1:10:10. In some embodiments, the fragrance composition comprises (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline, and (c) indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl, in a ratio of (a:b:c) ranging from about 1:2:2 to 1:5:5. In some embodiments, the fragrance composition comprises (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline, and (c) indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl, in a ratio of (a:b:c) of 1:1.5:1.5, 1:2:2, 1:4:4, 1:5:5, 1:10:10, or 1:20:20.In some embodiments, the fragrance composition comprises (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline, and (c) indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl, in a ratio of (a:b:c) of 1:2:2 or 1:4:4. In some embodiments, the fragrance composition comprises (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline, and (c) indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl, in a ratio of (a:b:c) of 1:4:4.

[0079] In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4 or 5% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.001% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.00125% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.005% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.01% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.05% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.1% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 0.5% by weight. In some embodiments, the fragrance composition comprises 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline at a concentration of at least or about 1% by weight.

[0080] In some embodiments, the fragrance composition comprises (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline, (c) indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl, and (d) 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline, in a ratio of (a:b:c:d) ranging from about 5:20:20:1 to 20:80:80:1. In some embodiments, the fragrance composition comprises: (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; (c) indeno[4,5-d]-1,3-dioxin, 4,4a,5,6,7, and (d) 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline in a ratio of (a:b:c:d) of 5:20:20:1 or 10:40:40:1 or about 5:20:20:1 or about 10:40:40:1. In some embodiments, the fragrance composition comprises (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one, (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline, (c) indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl, and (d) 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline, in a ratio of (a:b:c:d) of at or about 10:40:40:1.

[0081] In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 0.001, 0.005, 0.01, 0.05, 0.1, 0.5, 1, 2, 3, 4 or 5% by weight. In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 0.001% by weight. In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 0.00125% by weight. In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 0.005% by weight. In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 0.01% by weight. In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 0.05% by weight. In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 0.1% by weight. In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 0.5% by weight.In some embodiments, the fragrance composition comprises 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole at a concentration of at least or about 1% by weight.

[0082] In some embodiments, the fragrance composition comprises: (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; (c) indeno[4,5-d]-1,3-dioxin, 4,4a,5, and (d) 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole, in a ratio of (a:b:c:d) ranging from about 5:20:20:1 to 20:80:80:1. In some embodiments, the fragrance composition comprises: (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; (c) indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octyldodecyl ester; and (d) 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole in a ratio of (a:b:c:d) of 5:20:20:1 or 10:40:40:1 or about 5:20:20:1 or about 10:40:40:1. In some embodiments, the fragrance composition comprises: (a) 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; (b) 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; (c) indeno[4,5-d]-1,3-dioxin, 4,4a,5, and (d) 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole, in a ratio of (a:b:c:d) of at or about 10:40:40:1.

[0083] In some embodiments, concentrations in weight percent described herein (eg, concentrations described above) are based on the total weight of the composition.

[0084] In some embodiments, the fragrance compositions for improving sleep described herein further comprise a solvent. The solvents contemplated for use herein are described in more detail below.

[0085] In a particular aspect, the present disclosure provides a fragrance composition consisting of: (i) at least three heteroatom musk compounds; and (ii) at least one acyclic musk compound or 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline (Sinfonide®), and optionally a solvent.

[0086] In a particular aspect, the present disclosure provides a fragrance composition consisting of (i) at least three heteroatom musk compounds, and (ii) at least one acyclic musk compound, 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline or 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole, and optionally a solvent.

[0087] Solvents suitable for use in perfume compositions are those suitable for use in consumer products and, when combined with other components of the final product, do not render the consumer product unsuitable for its intended consumer user. Solvents are preferably those that do not alter or do not significantly alter the olfactory properties of perfume ingredients. Preferably, the solvent is selected from dipropylene glycol (DPG), isopropyl myristate, ethanol, triethyl citrate or combinations thereof. Non-limiting examples of other suitable solvents are known to those skilled in the art and include, but are not limited to, diethyl phthalate, benzyl benzoate, 2-(2-ethoxy)-1-ethanol, ethyl citrate, water / ethanol mixtures, limonene or other terpenes, isoparaffins such as those sold under the trademark Isopar (registered trademark) (ExxonMobil Chemicals, Houston, Texas) and glycol ethers and glycol esters such as those known under the trademark Dowanol (registered trademark) (Dow Chemical Company, Midland, Michigan), and the solvents disclosed in paragraph

[0120] of U.S. Patent Application Publication No. 2021 / 0008082A1 (Takasago International Corporation).

[0088] In certain embodiments, the heteroatom musk compounds, acyclic musk compounds, and / or 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline of the present disclosure may each independently be present in the fragrance composition at a concentration of from about 0.001% to about 100% by weight, or from about 0.01% to about 90% by weight, or from about 0.1% to about 80% by weight, or from about 1% to about 70% by weight, or from 1% to about 60% by weight, or from about 1% to about 50% by weight, or from about 1% to about 45% by weight.

[0089] In certain embodiments, the heteroatom musk compound, acyclic musk compound, 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline or 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole of the present disclosure may each independently be present in the fragrance composition at a concentration of from about 0.001% to about 100% by weight, or from about 0.01% to about 90% by weight, or from about 0.1% to about 80% by weight, or from about 1% to about 70% by weight, or from 1% to about 60% by weight, or from about 1% to about 50% by weight, or from about 1% to about 45% by weight.

[0090] In certain embodiments of the fragrance composition described herein above, the weight ratio of (i) to (ii) is from 55:1 to 45:1 or from 52:1 to 47:1.In other embodiments, the fragrance composition comprises (i) 95% to 99% by weight of heteroatom musk compounds; and (ii) 1% to 5% by weight of acyclic musk compounds or 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline, the weight percentages being based on the total weight of the composition. In some embodiments, the fragrance composition comprises: (i) 95% to 99% by weight of heteroatom musk compounds; and (ii) 1% to 5% by weight of the acyclic musk compounds, 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline or 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole, wherein the weight percentages are based on the total weight of the composition.

[0091] In some embodiments, heteroatom musk compounds that can effectively enhance the quantity and / or quality of sleep include, but are not limited to, indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl (Nebulone®); 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one (Cashmeran®); 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline (Ambertonic™); and combinations thereof. Other suitable examples of heteroatom musk compounds will be known to those skilled in the art.

[0092] In certain embodiments, the present disclosure provides a fragrance composition comprising a heteroatomic musk compound and an acyclic musk compound, wherein (i) the heteroatomic musk compound is indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and (ii) the acyclic musk compound is 1-propanol, 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methyl-, 1-propanoate (Helvimor). Other suitable examples of acyclic musks will be known to those skilled in the art.

[0093] In a specific embodiment, the fragrance composition comprises 40% to 45% by weight of indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 5% to 15% by weight of 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 40% to 45% by weight of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and 0.1% to 5% by weight of 1-propanol, 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methyl-, 1-propanoate, the weight percentages being based on the total weight of the composition.

[0094] In another embodiment, the fragrance composition comprises a heteroatomic musk compound and 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline (Sinfonide®), wherein the heteroatomic musk compound is indeno[4,5-d]-1,3-dioxine; 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline.

[0095] In a specific embodiment, the composition comprises 40% to 45% by weight of indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 5% to 15% by weight of 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 40% to 45% by weight of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and 0.1% to 5% by weight of 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline.

[0096] In another embodiment, the fragrance composition comprises a heteroatomic musk compound and 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole, where the heteroatomic musk compound is indeno[4,5-d]-1,3-dioxine; 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline.

[0097] In a specific embodiment, the composition comprises 40% to 45% by weight of indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 5% to 15% by weight of 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 40% to 45% by weight of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and 0.1% to 5% by weight of 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole.

[0098] In a particular embodiment, the present disclosure provides a fragrance composition that can improve sleep. Preferably, the improved sleep includes at least one or more sleep effects. In a particular embodiment, the fragrance composition provides improved sleep including at least one or more sleep effects selected from the list including improved sleep quality, increased total sleep time, decreased wake-after-sleep-onset (WASO), decreased %Wake after sleep onset, increased deep sleep (N3 / N4) time, increased % of time spent in deep sleep (N3 / N4), increased REM sleep time, increased % of time spent in REM sleep, increased light sleep (N1 / N2) time, increased % of time spent in light sleep (N1 / N2), increased sleep efficiency, increased sleep maintenance, decreased number of sleep awakenings, decreased time to fall asleep, increased feeling of rest, increased feeling of refreshment upon and / or after awakening, increased feeling of recovery, increased feeling of being ready for the day's activities, decreased daytime sleepiness, or combinations thereof. Preferably, the sleep effect is biometric or biosensed.

[0099] In another embodiment, the present disclosure provides a fragrance composition capable of improving sleep, the sleep improvement comprising at least one or more sleep benefits selected from the list comprising reduced time to fall asleep, reduced time awake at night (WASO), increased sleep efficiency, increased sleep maintenance, increased time in deep sleep, increased percentage of time spent in deep sleep stages, improved quality of sleep, increased feeling of restedness or combinations thereof, preferably the sleep benefit is bio-measured or bio-sensed.

[0100] In certain embodiments, the fragrance composition of the present disclosure may contain at least one or more additional fragrance ingredients of various kinds, so long as the addition of the ingredients does not change or does not substantially change the ability of the composition to increase the amount of sleep and / or improve the quality of sleep. Preferably, the fragrance composition may contain at least one, at least two, at least three, at least four, at least five, at least six, at least seven, at least eight, at least nine, or at least ten additional fragrance ingredients. The additional fragrance ingredients are combined with the musk compounds to form the completed fragrance composition. In this regard, the 100% by weight balance of the total weight of the fragrance composition is composed of (i) at least three heteroatom musk compounds; (ii) at least one acyclic musk compound or 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; and (iii) one or more additional fragrance ingredients. In some embodiments, the additional perfume ingredients are combined with the compound having the skeletal structure of formula (I) to form a complete perfume composition. In some embodiments, the 100% weight balance of the total perfume composition is made up of (i) one or more compounds having the skeletal structure of formula (I) and (ii) one or more additional perfume ingredients. In some embodiments, the weight % of the one or more compounds having the skeletal structure of formula (I) is any of the weight % values ​​described herein. In some embodiments, the 100% weight balance of the total perfume composition is made up of (i) one or more compounds having the skeletal structure of formula (I), the total concentration of the one or more compounds being at least 0.05% by weight or greater than 0.05% by weight, and (ii) one or more additional perfume ingredients. In some embodiments, the balance of 100% by weight of the total weight of the fragrance composition is comprised of: (i) one or more compounds having a backbone structure of formula (I); (ii) at least one acyclic musk compound; and (iii) one or more additional fragrance ingredients.In some embodiments, the weight percent of one or more compounds having a skeletal structure of formula (I) is any weight percent described herein, and the weight percent of at least one acyclic musk compound is any weight percent described herein, which together with the one or more ingredients totals 100%. In some embodiments, the balance of 100% by weight of the total weight of the fragrance composition is made up of (i) one or more compounds having a skeletal structure of formula (I), the one or more compounds having a total concentration of at least 0.05% by weight or more than 0.05% by weight, (ii) at least one acyclic musk compound having a total concentration of at least 0.0025% by weight, and (iii) one or more additional fragrance ingredients. In some embodiments, the additional fragrance ingredients are combined with one or more heteroatom musk compounds to form the complete fragrance composition. In some embodiments, the 100% by weight formula balance based on the total weight of the fragrance composition comprises (i) one or more heteroatomic musk compounds, and (ii) one or more additional fragrance ingredients. In some embodiments, the weight percent of the one or more heteroatomic musk compounds is any weight percent described herein. In some embodiments, the 100% by weight formula balance based on the total weight of the fragrance composition is comprised of (i) one or more heteroatomic musk compounds, the total concentration of the one or more compounds being at least 0.05% by weight or greater than 0.05% by weight, and (ii) one or more additional fragrance ingredients. In some embodiments, the 100% by weight formula balance based on the total weight of the fragrance composition is comprised of (i) one or more heteroatomic musk compounds, (ii) at least one acyclic musk compound, and (iii) one or more additional fragrance ingredients. In some embodiments, the weight percentage of the one or more heteroatom musk compounds is any weight percentage described herein, and the weight percentage of the at least one acyclic musk compound is any weight percentage described herein, with the total weight percentages added together with the one or more components to add up to 100%.In some embodiments, the balance of the formula of 100% by weight based on the total weight of the fragrance composition is made up of: (i) one or more heteroatom musk compounds, the one or more compounds having a total concentration of at least or greater than 0.05% by weight; (ii) at least one acyclic musk compound having a total concentration of at least 0.0025% by weight; and (iii) one or more additional fragrance ingredients.

[0101] In certain embodiments, the additional perfume ingredient may be, but is not limited to, one or more aldehydic compounds, one or more animalic compounds, one or more balsamic compounds, one or more citrus compounds, one or more floral compounds, one or more fruity compounds, one or more gourmand compounds, one or more green compounds, one or more herbal compounds, one or more marine compounds, one or more mossy compounds, one or more piney compounds, one or more powdery compounds, one or more spicy compounds, one or more woody compounds, one or more licorice compounds, or combinations thereof.

[0102] Suitable examples of additional perfume ingredients are described in US 2020 / 0048578 A1 (Givaudan), US 2018 / 0325786 A1 (IFF) and US 4,534,891 (IFF). Further non-limiting examples of such additional fragrance ingredients are ALDEHYDE C 10 DECYLIC; ALDEHYDE C 11 UNDECYLENIC; ALDEHYDE C 110 UNDECYLIC; ALDEHYDE C 12 LAURIC; ALDEHYDE C 12 MNA PURE; ALDEHYDE C 8 OCTYLIC FOOD GRADE; ALDEHYDE C 9 ISONONYLIC; ALDEHYDE C 9 NONYLIC FOOD GRADE; ALDEHYDE C 90 NONENYLIC 1% / TEC; ALDEHYDE C12 (DODECANAL); ALDEHYDE ISO C 11; MANDARINAL; trans-4-DECENALE, DECENAL-4-TRANS 10% / TEC; DIHYDROFARNESAL; DODECANAL; MYRALDENE; TANGERINOL; AMBERKETAL®; IPM;AMBERMAX;AMBROCENIDE®;AMBROFIX;AMBROFIX FLAKES;BELAMBRÉ;BOISAMBRENE FORTE;CEDRYL ACETATE LIQUID;CEDRYL METHYL ETHER;CETALOX;ISO E SUPER;KARANAL;KEPHALIS;TIMBEROL;TRIMOFIX O;ANIMALIS 1745 SUBST.PMF 2;JUMP OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES, REPLACEMENTS;GUAIACOL;INDOFLOR;INDOLE;INDOLENE;ANETHOLE;ANISE STAR OIL;ANISIC ALDEHYDE;ANISYL ACETATE;DIHYDRO ANETHOLE;ESTRAGOLE;FENNEL OIL, ESSENTIAL OIL, EXTRACTS, BASES, SUBSTITUTES OR REPLACEMENTS;FENNEL SWEET DQ(AC)N 41632TT;FENNEL OIL SWEET;AND FENNEL OIL SWEET TECH;benzoin oil, essential oil, extract, substitute or alternative;BENZYL ALCOHOL;BENZYL CINNAMATE;BOYS OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;OLIBANUM OIL SOMALIA ORPUR;PHENYL ETHYL PHENYL ACETATE;ARTEMIA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CAMPER AND CAMPER OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;EUCALYPTOL AND EUCALYPTOL OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;LAVANDIN OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;LAVANDER OIL, EXTRACTS, ESSENTIAL OIL, SUBSTITUTES OR REPLACEMENTS;ROSEMARY OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;AND HIBA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;ACETAL CD;AMYL CINNAMIC ALDEHYDE;AMYL SALICYLATE;AURANTIOL PURE BENZYL ACETATE;BENZYL SALICYLATE;BOURGEONAL;CITRONELLOL;CITRONELLYL ACETATE;CRESYL METHYL ETHER PARA;CYCLAMEN ALDEHYDE EXTRA;CYCLOHEXAL;CYCLOHEXYL SALICYLATE;DIMETHYL ANTHRANILATE;DIMETHYL PHENYL THYL CARBINOL;DUPICAL;ETHYL LINALOOL;FLOROSA;FLOROSA HC;GERANIOL;Geranium oil, essential oil, extract, substitute or alternative;GERANODYLE;GERANYL ACETATE;GERANYL BUTYRATE;HEDIONE;HEDIONE HC;HEXENYL-3-CIS SALICYLATE;HEXYL CINNAMIC ALDEHYDE;HEXYL CINNAMIC ALDEHYDE DQ AC XI 41505TT;HEXYL SALICYLATE;HYDROXYCITRONELLAL;ISOBUTYL PHENYL ACETATE;ISOBUTYL SALICYLATE;JASMATONE;JASMINE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;JASMONE CIS;JASMONYL;JASMOPYRANE FORTE;LILIAL AND LILIAL SUBSTITUTES;LINALOOL;MEFROSOL;METHYL ANTHRANILATE;METHYL ANTHRANILATE EXTRA;METHYL BENZOATE;METHYL PHENYL ACETATE;NEROLINE CRYSTALS;NEROLIONE;ORANGER CRYSTALS;ORANGER FLEUR CREME 1103 / 20;PELARGOL;PEONILE;PETALIA;PHENYL ETHYL ACETATE;PHENYL ETHYL ALCOHOL;PHENYL ETHYL ISOVALERATE;PHENYL ETHYL SALICYLATE CRYSTALS;ROSACETOL;ROSALVA;SUPER MUGUET;TERPINEOL PURE;TETRAHYDRO LINALOOL;VERDANTIOL;YARA YARA;IRAN OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;ACETATE C 6 HEXYLIC;AGRUMEX;ALLYL AMYL GLYCOLATE;ALLYL CAPROATE;ALLYL CYCLOHEXYL PROPIONATE;ALLYL OENANTHATE;AMYL BUTYRATE;APHERMATE;APHERMATE;APHERMATE;BANANA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;BENZYL BUTYRATE;BENZYL ISOBUTYRATE;BENZYL PROPIONATE;BUTYL ACETATE;BUTYRIC ACID;BLACKCURST OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;COGNAC WHITE OIL EXTRA DQ(AC)41547TT;CYCLOGALBANATE;DAMASCENONE;DAMASCONE ALPHA;DAMASCONE BETA;DAMASCONE DELTA;DECALACTONE DELTA;DECALACTONE GAMMA;DEWFRUIT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;DIETHYL MALONATE;DIMETHYL BENZYL CARBINYL ACETATE;DIMETHYL BENZYL CARBINYL BUTYRATE;DODECALACTONE DELTA;DODECALACTONE GAMMA;ETHYL ACETOACETATE;ETHYL BUTYRATE;ETHYL CAPROATE;ETHYL CAPRYLATE;ETHYL ISOAMYL KETONE;ETHYL ISOBUTYRATE;ETHYL METHYL-2-BUTYRATE;ETHYL OENANTHATE;ETHYL PELARGONATE;ETHYL PROPIONATE;ETHYL SAFRANATE;FLOROCYCLENE;FRAISTONE;FRUCTONE;FRUITATE;GARDOCYCLENE;GIVESCONE;Guava oil, essential oil, extract, substitute or alternative;HEXENYL-3-CIS BUTYRATE;HEXENYL-3-CIS ISOBUTYRATE;HEXYL BUTYRATE;HEXYL ISOBUTYRATE;ISOAMYL ACETATE EXTRA;ISOAMYL BUTYRATE FR;JASMACYCLENE;MANZANATE;MELON OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;METHOXY PHENYL BUTANONE;METHYL HEPTENONE PURE;METHYL HEXYL KETONE;METHYL-2-PENTENOIC ACID;2-NECTARYL;OCTALACTONE GAMMA;PEACH PURE;PHENOXY ETHYL ISOBUTYRATE;PHENYL ETHYL ISOBUTYRATE;PRUNOLIDE;RASPBERRY KETONE(N 112);AND STRAWBERRY PURE;AMYL VINYL CARBINOL;OCIMENE;ACETOIN;ACETYLPYRAZINE;BENZALDEHYDE;BUTYL BUTYRO LACTATE;CHOCOLATE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CORYLONE DRIED;CYCLOTENE;ETHYL MALTOL;HOMOFURONOL;HYDROXYETHYL METHYLTHIAZOLE;ISOBUTAVAN;AND MALTYL ISOBUTYRATE;ACETAL E;ALCOHOL C 6 HEXYLIC;ALDEHYDE C 6 HEXYLIC FOOD GRADE;BUTYL QUINOLINE SECONDARY;CYCLAL C;DIPHENYL OXIDE;ELINTAAL;ETHYL DECADIENOATE;ETHYL DIMETHYLPYRAZINE;GALBANONE;GARDENOL;trans-2-HEXENAL;HEXENOL-2-TRANS;HEXENOL-3-CIS;HEXENYL-3-CIS ACETATE;HEXENYL-3-CIS BENZOATE;HEXENYL-3-CIS PROPIONATE;ISOCYCLOCITRAL;ISOHEXYL METHOXYPYRAZINE;LIFFAROME;LIGANTRAAL;MACEAL;METHYL OCTYNE CARBONATE;NEOFOLIONE;NONADIENOL-2,6;cis-6-NONADIENOL;NONENOL-6-CIS;PETITGRAIN OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;PHENOXYACETALDEHYDE;PYRALONE;RESEDAL;ROSE OXIDE;ROSYRANE SUPER;STEMONE;TRICYCLAL;TRIFERNAL;UNDECATRIENE;UNDECAVERTOL;VIOLET NITRILE;VIRIDINE;BASIL OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CAMOMILE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CITRONELLAL;SALVIA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CYPRISATE;EUCALYPTUS OIL, EXTRACTS, ESSENTIAL OIL, SUBSTITUTES OR REPLACEMENTS;HERBOXANE;PINOACETALDEHYDE;TANAISONE;THYMOL CRYSTALS;ADOXAL;AZULONE;CALONE 1951;FENNALDEHYDE;FLORALOZONE;FLORHYDRAL;MELONAL;SCENTENAL;TROPIONAL;and VERNALDEHYDE;BUTU LEAF OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CARVONE LAEVO;CORN MINT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;FRESKOMENTHE;ISOMENTHONE DL;MENTHOL LAEVO;MENTHOL-DL;MENTHONE;MENTHYL ACETATE;PEPTINE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;AND SPEARMINT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;AMBRETTOLIDE;CASHMERAN;COSMONE;CYCLOPENTADECANOLIDE;ETHYLENE BRASSYLATE;GALAXOLIDE;GALAXOLIDE S;HABANOLIDE;MUSCENONE;MUSK C14;SERENOLIDE;SILVANONE SUPRA;SYLKOLIDE;VELVIONE;CETONE; V;DIHYDRO IONONE BETA;IONONE BETA;IRISONE ALPHA;IRISONE PURE;ISORALDEINE 70;ISORALDEINE 95;ORIVONE;ANGELIC;Corps cassis;Corps pamplemousse;DIMETHYL SULFIDE;GARDAMIDE;LAVIENOXIM;MERCAPTAN;METHYL ISOPROPYL THIAZOLE;NARDOSTE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;NEOCASPIRENE EXTRA;NONIVAMIDE 1% TRIACETIN;OXANE;PARADISAMIDE;PARAMENTONE;ACETOPHENONE;AUBEPINE PARA CRESOL;BICYCLO NONALACTONE;COUMARIN;ETHYL LIGHTONE;ETHYL VANILLIN;HELIOTROPIN;Vanilla oil, essential oil, extract, substitute or substitute;VANILLIN;Vanolia oil, essential oil, extract, substitute or substitute;VERATRIC ALDEHYDE;BORNEOL;BORNYL ACETATE LIQUID;BUTYL CYCLOHEXANOL PARA;BUTYL CYCLOHEXYL ACETATE PARA;JUNIOR PINK OIL, essential oil, extract, substitute or substitute;CONIFERAN;EBANOL;EVERNYL;FENCHYL ACETATE;GUAIAC WOOD OIL, essential oil, extract, substitute or substitute;ISONONANYL ACETATE;JAVANOL;KOHINOOL;MENTHANYL ACETATE;METHYL CEDRYL KETONE;NOPYL ACETATE;OSYROL;OXYOCTALINE FORMATE; PATCHOULI OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; PINENE ALPHA; PINENE BETA; RADJANOL; RADJANOL SUPER; TURBINE, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; VERTOFIX COEUR; AND VETIVER OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; ALDEHYDE C12; and MENTHYL ACETATE.

[0103] In some embodiments, the fragrance composition described herein may be blended with an existing accord, draft or finished fragrance. In some embodiments, the accord, draft or finished fragrance may not have a sleep-improving effect as described herein. In some embodiments, the fragrance composition for sleep improvement described herein may be blended with an accord, draft or finished fragrance that does not have a sleep-improving effect to obtain an accord, draft or finished fragrance with a sleep-improving effect. For example, the fragrance composition for sleep improvement described herein may be added to an existing accord, draft or finished fragrance to obtain an accord, draft or finished fragrance with a sleep-improving effect. Thus, in some cases, the fragrance composition for sleep improvement described herein may impart a sleep-improving effect to a fragrance that does not affect sleep.

[0104] In certain embodiments, the fragrance composition of the present disclosure is substantially free or essentially free of one or more musk compounds, provided that the one or more musk compounds do not include heteroatom musk compounds and / or acyclic musk compounds.In certain embodiments, the fragrance composition is substantially free or essentially free of macrocyclic musk compounds, preferably including Ambretone®, ambrettelide, Cosmone®, cyclopentadecanolide, ethylene brassylate, Habanolide®, L-muscone, muscenone, musk C14, Musk T®, Silvanone® Supra and / or Velvione®.

[0105] The perfume compositions of the present disclosure may contain one or more perfume co-ingredients, generally belonging to, but not limited to, the following chemical classes: alcohols, aldehydes, ketones, esters, ethers, acetals, oximes, acetates, nitriles, terpenes, saturated and unsaturated hydrocarbons of natural or synthetic origin.

[0106] Pure perfume. In certain embodiments, the perfume composition of the present disclosure comprises a pure perfume. "Pure perfume" refers to a perfume ingredient that is free of extraneous substances, is not encapsulated, and / or is not associated with other compounds that would delay the release of the perfume ingredient. When the perfume ingredient is a pure perfume, the perfume ingredient is present in an amount of 0.001% to 100% by weight based on the total weight of the perfume composition.

[0107] In some embodiments, the compound or compounds having the backbone structure of formula (I) are pure perfumes. In some embodiments, the heteroatom musk compound or compounds are pure perfumes. In some embodiments, the acyclic musk compound is pure perfumes.

[0108] Encapsulated perfume. In certain embodiments, the sleep benefits of the perfume composition of the present disclosure can be further improved by utilizing a delivery system for such perfume compounds. Typically, microcapsules are used to encapsulate perfumes and deliver them to target areas in a delayed or controlled manner. The term "encapsulated perfume" as used herein refers to perfume compositions encapsulated in microcapsules to stabilize the release of perfume compounds over an extended period of time. Without wishing to be bound by a particular theory, the applicant proposes that the perfume composition can be applied to pillowcases and / or bedding from various consumer products (e.g., fabric sprays, laundry detergents, fabric softeners, fragrance enhancers, etc.). Then, during the night, the subject rubs the pillowcase and / or bedding, causing the microcapsules to burst and the perfume material to be released from the microcapsules. As a result, the released perfume composition acts to improve the quality and / or quantity of sleep continuously throughout the night.

[0109] The average particle size of the microcapsules is preferably 1 to 100 microns, preferably 1 to 50 microns, more preferably 1 to 20 microns. Microcapsules can be prepared from natural materials such as mycelium chitosan (WO 2016 / 185171 A1), silk fibroin particles (US 2015 / 0164117 A1) and biomolecules used as emulsifiers in microcapsule preparation (WO 2016 / 193435 A1; WO 2017 / 102812 A1; US ​​2018 / 0078468 A1; WO 2018 / 019894 A1; WO 2018 / 019896 A1; and WO 2017 / 102812 A1). Multilayer coacervates of gelatin / gum arabic capsules can be used in the present invention (U.S. Pat. No. 4,946,624; WO 2012 / 001604 A1; U.S. Pat. App. Pub. No. 2015 / 0250689 A1; and WO 2018 / 002214 A1). Protein microcapsules are also useful within the scope of the present invention (U.S. Pat. App. Pub. No. 2017 / 0189283 A1). Environmentally friendly microcapsules, preferably with a shell biodegradability of at least 60% by weight within 60 days according to OECD 301F, are also useful within the scope of the present invention (WO 2021 / 122633 A1).

[0110] In some embodiments, one or more compounds having a skeletal structure of formula (I) are encapsulated. In some embodiments, one or more heteroatom musk compounds are encapsulated. In some embodiments, the acyclic musk compounds are encapsulated. In certain embodiments of the present disclosure, the perfume ingredients are pure perfumes (i.e., unencapsulated perfumes), encapsulated perfumes, or combinations thereof. One or more compounds having a skeletal structure of formula (I), one or more heteroatom musk compounds, and acyclic musk compounds can be considered as perfume ingredients of a perfume composition.

[0111] Use of fragrance compositions in consumer products

[0112] The fragrance composition of the present disclosure according to any embodiment described herein can be advantageously formulated as part of a consumer product for improving nighttime sleep, preferably for improving at least one sleep benefit of a subject. Such consumer products can be prepared in any suitable form by any process selected by the formulator. The concentration of the fragrance composition mixed with the consumer product to provide at least one sleep benefit to a subject can vary based on many variables, such as the specific type of consumer product, the physical form of the consumer product (e.g., liquid, gas, or solid), and other fragrance ingredients and their concentrations already present in the consumer product.

[0113] In some embodiments, the consumer products of the present disclosure are air care products (e.g., candles, incense, aerosols, air fresheners, electric liquid air fresheners, fragrance diffusers, high performance diffusers, gel air fresheners, or plug-in air fresheners), fabric care products (e.g., laundry detergents, fabric softeners, pillow sprays, fabric cleaners, fragrance enhancers, laundry unit dose articles, or dryer sheets), personal care products (e.g., lotions, creams, wipes, body washes, hand soaps, soaps, skin patches, and the like), pet care products, hygiene products (e.g., towels, toilet paper, tissue papers, The consumer product may be, but is not limited to, a cosmetic product, such as a towel, a towelette, a handkerchief, a towelette, a fine fragrance (e.g., parfum, eau de parfum, eau de cologne, eau de toilette, etc.), a hair care product (e.g., shampoo, rinse, conditioner, leave-in shampoo, hair styling product, etc.) or a beauty care product (e.g., skin cream, stain remover cream, night cream, hand cream, toner, aftershave lotion, body lotion, lip balm, talcum powder, anti-wrinkle and / or anti-aging cosmetics, massage oil, etc.). In some embodiments, the consumer product is a product used for sleep or pre-bedtime routine. For example, the consumer product may be bedding, such as linens (e.g., bed sheets, pillowcases, etc.), bedding (e.g., comforters, bed covers, duvets, blankets, etc.) or bed elements themselves (e.g., mattresses, pillows, bed frames, etc.). In some embodiments, the consumer product is a pre-sleep or sleep aid. For example, the consumer product may be a pillow core, a mattress core, a pillow sachet, an eye mask, or other product designed to incorporate a fragrance composition for sleep improvement into the material of the product. In some embodiments, the air care product includes a device for delivering the fragrance composition, such as those described above. In some embodiments, the device is a wearable device. In some embodiments, the device is a smart device, such as a smart bed, a smart mattress, a smart pillow, a smart wearable device.

[0114] The fragrance composition can be used in a wide range of concentrations to provide at least one sleep benefit to a subject.In certain embodiments of the present disclosure, the fragrance composition can be mixed with a consumer product, and the composition can be present in the consumer product in an amount of about 1 to about 9000 ppm, or about 5 to 7500 ppm, or about 10 to about 5000 ppm, or about 50 to 2500 ppm, or about 100 to 1000 ppm, or about 250 to 500 ppm, and any value therebetween.

[0115] In certain embodiments of the present disclosure, the fragrance composition can be mixed with a consumer product, and the composition is present in an amount of about 0.0001% to about 90% by weight, or about 0.001% to about 75% by weight, or about 1% to 50% by weight, and any value therebetween. In some embodiments, the fragrance composition is present in an amount effective to enhance at least one sleep benefit. In some embodiments, the effective amount depends on the amount, e.g., total concentration, of the compound having the structure of formula (I). In some embodiments, the effective amount depends on the amount, e.g., total concentration, of the heteroatomic musk compound. In some embodiments, the effective amount is an amount, e.g., total concentration, of 0.05% by weight or more. In some embodiments, the effective amount is an amount, e.g., total concentration, of 0.1% by weight or more. In some embodiments, the effective amount is an amount, e.g., total concentration, of 1% by weight or more. In some embodiments, the consumer product may comprise a fabric softener active selected from the group consisting of one or more additional bases, solvents, other perfume compounds, perfume co-ingredients, builders, chelating agents, dye transfer inhibitors, dispersants, enzymes and enzyme stabilizers, catalytic materials, bleach activators, hydrogen peroxide, hydrogen peroxide sources, preformed peracids, polymeric dispersants, mud stain removal / anti-redeposition agents, brighteners, suds suppressors, dyes, whitening dyes, perfumes, perfume delivery systems, structure elastomers, carriers, structurants, hydrotropes, processing aids, solvents in addition to the solubilizers; silicone polymers, polysaccharides / clays, fatty esters, dispersible polyolefins, polymeric latexes, pigments, and combinations thereof.

[0116] The perfume composition disclosed herein is particularly suitable for use in fabric care products, preferably as fabric sprays, laundry detergents, fabric softeners and fragrance enhancers, more preferably as pillow and / or bedding sprays. In certain embodiments, the fabric spray composition of the present disclosure is an aqueous fabric spray. Preferably, at least 60% by weight of the composition, more preferably at least 70% by weight, is water. In certain embodiments, the fabric spray composition of the present disclosure comprises pure perfume, preferably present in an amount selected from less than 10% by weight, less than 8% by weight, and less than 5% by weight of the spray composition. In yet another embodiment of the present disclosure, the fabric spray composition comprises a combination of pure and encapsulated perfume.

[0117] The fabric spray composition of the present invention preferably includes a malodor control component. The malodor control agent may be present in an amount selected from less than 20% by weight, less than 10% by weight, and less than 5% by weight of the fabric spray composition. Any suitable malodor control agent may be used. Non-limiting examples of malodor control agents may be selected from the group consisting of uncomplexed cyclodextrin; odor blockers; reactive aldehydes; flavonoids; zeolites; activated carbon; mixtures of zinc ricinoleate or a solution thereof with substituted monocyclic organic compounds; and mixtures thereof. Without wishing to be bound by a particular theory, the applicant proposes that the use of a malodor control agent together with the present fragrance composition will help capture, absorb, or destroy unpleasant odor molecules emanating from the pillowcase and / or bedding, further improving sleep benefits.

[0118] In certain embodiments, the subject matter of the present disclosure relates to a method of incorporating a fragrance composition that provides sleep-improving benefits into a consumer product. According to this embodiment, the method may include: (a) providing at least one consumer product; and (b) combining the consumer product with a fragrance composition as described herein. In certain embodiments, such a composition may be administered before a subject's usual bedtime.

[0119] In yet another embodiment, the composition of the present disclosure is useful for improving sleep and can be advantageously formulated into consumer products intended to be applied to any substrate.The term "substrate" as used herein means any surface to which the composition of the present invention can be applied without causing excessive side effects.For example, this can include a wide range of surfaces, such as human or animal skin or hair, fabrics (pillow sprays), air (air fresheners), furniture, paper, tableware, hard surfaces and related materials.Preferred substrates include fabrics, such as bedding, laundry, blankets and pillowcases.

[0120] How to improve your sleep

[0121] In certain embodiments, the present disclosure relates to a method for improving at least one sleep effect in a subject, the method comprising providing a fragrance composition as described herein or a consumer product as described herein to the subject in an amount effective to improve at least one sleep effect. Preferably, the fragrance composition or consumer product is (i) sprayed or applied to the subject (e.g., a body part, face or hair); (ii) sprayed or applied to furniture upholstery or fabric, preferably bedding, laundry, blankets or pillowcases; and / or (iii) dispersed or diffused in the air (in a room). Preferably, the at least one sleep effect is preferably selected from the group consisting of improved sleep quality, increased total sleep time, reduced awakening after sleep onset (WASO), reduced %Wake after sleep onset, increased time in deep sleep (N3 / N4), increased % of time spent in deep sleep (N3 / N4), increased time in REM sleep, increased % of time spent in REM sleep, increased time in light sleep (N1 / N2), increased % of time spent in light sleep (N1 / N2), increased sleep efficiency, increased sleep maintenance, reduced number of awakenings during sleep, reduced time to fall asleep, increased feeling of rest, increased feeling of refreshment upon and / or after awakening, increased feeling of recovery, increased feeling of being ready for the day's activities, reduced daytime sleepiness or a combination thereof, preferably the sleep effect is biomeasured or biosensed. In another embodiment, a method of enhancing at least one sleep benefit in a subject comprises incorporating a fragrance composition described herein or a consumer product described herein into the consumer's sleep ritual before, just before, or during bedtime by providing the subject with an amount effective to enhance at least one sleep benefit.

[0122] In some embodiments, the fragrance composition may be provided by a device. For example, in some embodiments, the fragrance composition may be contained in a wearable fragrance delivery device and provided to a subject from there. In some embodiments, the fragrance composition is used in conjunction with a smart device, such as a smart bed, a smart mattress, a smart pillow, a smart wearable device, etc., to provide the fragrance to the subject. In some embodiments, the smart device further collects data, such as biometric data from the subject, and uses the data to regulate (e.g., start, stop, increase, decrease) the delivery of the fragrance. The fragrance composition may be present in any form suitable for use in such a device.

[0123] In certain embodiments, the fragrance composition is administered to the subject in gaseous or volatile form. In certain non-limiting embodiments, the fragrance composition can be administered intranasally or by inhalation. In certain embodiments, the subject can inhale the fragrance composition directly or indirectly. In other specific embodiments, the fragrance composition can be released into the area around the subject, and the subject inhales the composition. In specific embodiments, the composition is released into the air by a consumer product, such as, but not limited to, an air freshener or a candle, or bedding and / or pillowcases treated with one or more fabric care products, such as fabric sprays, laundry detergents, fabric softeners, fragrance enhancers, etc. In some embodiments, the consumer product is a bedtime or sleep aid. In some embodiments, the consumer product is a device, such as a smart device.

[0124] In certain embodiments of the present disclosure, the amount of the fragrance composition released from the consumer product may be less than the total concentration of the fragrance composition mixed with the consumer product. In certain embodiments, the amount of the fragrance composition released from the consumer product, and therefore available for administration to a subject, may be from about 1% to about 100% of the amount of the fragrance composition mixed with the consumer product. In further embodiments, the amount of the fragrance composition released may be from about 5% to about 90%, from about 10% to about 80%, from about 20% to about 70%, from about 30% to about 60%, and from about 40% to about 50% of the amount of the fragrance composition mixed with the consumer product.

[0125] In other embodiments, the subject matter disclosed herein may include consumer products containing a sufficient amount of a fragrance composition disclosed herein to provide a concentration of at least about 1 ng per cubic foot of air, at least about 5 ng per cubic foot of air, at least 10 ng per cubic foot of air, at least 20 ng per cubic foot of air, at least 30 ng per cubic foot of air, or at least 50 ng per cubic foot of air.

[0126] The present disclosure also provides a method for improving at least one sleep effect given to a subject in need thereof, comprising administering any of the disclosed fragrance compositions or consumer products in an amount effective to improve at least one sleep effect.Preferably, the subject is exposed to such fragrance composition or consumer product before bedtime, at bedtime and / or during the night.In a specific embodiment, the subject may be exposed to the fragrance composition or consumer product for at least about 15 minutes, at least about 30 minutes, at least about 1 hour, at least about 2 hours, at least about 3 hours, at least about 4 hours, at least about 5 hours, at least about 6 hours or at least about 7 hours.

[0127] The fragrance compositions described herein are intended to be used in a variety of environments, from residential to commercial spaces. For example, the fragrance compositions described herein may be used in private residences, such as subject bedrooms, and in commercial environments, such as hotels, such as hotel rooms.

[0128] How to monitor your sleep effectiveness

[0129] The sleep effect of the subject exposed to the fragrance composition can be monitored using, but not limited to, telemetry using the SleepScore Max device (SleepScore Labs, Carlsbad, California), a non-contact monitoring device that measures the subject's respiratory signal (i.e., breathing) and movement to detect sleep behavior. The sleep monitoring method of the present disclosure represents a significant advance in technology compared to conventional simple consumer-wearable sleep and health monitoring devices sold under the brand names Fitbit Inspire HR®, Fitbit Charge 5®, Fitbit Versa 2®, Fitbit Ionic®, Jawbone Up3®, OURA Ring Gen 3®, and other similar devices. A major drawback of these wearable sleep monitoring devices is that they may disrupt the subject's sleep patterns and / or may have limited sensors (e.g., heart rate sensors (i.e., sleep heart rate), motion detectors (indicators of restless sleep), etc.) and therefore may only provide minimal and / or vague sleep data and / or indicators. Conclusions drawn based on data generated from these devices may then not be particularly robust and / or may not properly support various sleep effects.

[0130] Therefore, the sleep monitoring of the present disclosure is considered to be comparable to polysomnography (PSG), the gold standard of sleep assessment technology. The SleepScore Max device has been shown to have high performance in terms of sleep / wake measurements (Chinoy, ED et al., Performance of Seven Consumer Sleep-Tracking Devices Compared with Polysomnography, Sleep J., 2021, pp.1-16). The sleep monitoring method of the present disclosure allows the measurement of overall sleep quality indicators such as time spent in each sleep stage (light, deep and REM), total sleep time, wake-after-sleep (WASO), number of awakenings or number of awakening episodes, sleep onset latency, total wake time, time in bed, start time of sleep habit, end time of sleep habit (wake-up time), and sleep efficiency, sleep maintenance, sleep score, mental score and physical score.

[0131] The present invention will be described in more detail with the following non-limiting examples. Without further elaboration, it is believed that a person skilled in the art can utilize the present invention to its fullest extent based on the description herein. All publications cited herein are incorporated herein by reference in their entirety.

[0132] Exemplary embodiments Provided embodiments include: 1. A fragrance composition for improving sleep, comprising at least four fragrance ingredients comprising: (i) at least three heteroatom musk compounds; and (ii) at least one acyclic musk compound or 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline, and optionally a solvent selected from dipropylene glycol (DPG), isopropyl myristate, ethanol, triethyl citrate, or a combination thereof. 2. The fragrance composition according to embodiment 1, wherein the mass ratio of (i) to (ii) is from 55:1 to 45:1, or from 52:1 to 47:1. 3. The fragrance composition according to embodiment 1, comprising: 3.95% to 99% by weight of heteroatomic musk compounds; and 1% to 5% by weight of acyclic musk compounds or 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline, wherein the weight percentages are based on the total weight of the composition. 4. The fragrance composition of embodiment 1, wherein the heteroatom musk compounds are indeno[4,5-d]-1,3-dioxine; 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline. 5. The fragrance composition according to embodiment 1, comprising a heteroatomic musk compound and an acyclic musk compound, wherein (i) the heteroatomic musk compound is indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and (ii) the acyclic musk compound is 1-propanol, 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methyl-, 1-propanoate. 6. The fragrance composition of embodiment 5, comprising: 40% to 45% by weight of indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 5% to 15% by weight of 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 40% to 45% by weight of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and 0.1% to 5% by weight of 1-propanol, 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methyl-, 1-propanoate, the weight percentages being based on the total weight of the composition. 7. The fragrance composition according to embodiment 1, comprising a heteroatomic musk compound and 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline, wherein the heteroatomic musk compound is indeno[4,5-d]-1,3-dioxine; 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline. 8. The fragrance composition according to embodiment 7, comprising 40% to 45% by weight of indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 5% to 15% by weight of 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 40% to 45% by weight of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and 0.1% to 5% by weight of 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline. 9. The fragrance composition according to embodiment 1, wherein the sleep improvement comprises at least one or more sleep effects selected from the list comprising improved sleep quality, increased total sleep time, reduced awakening after sleep onset (WASO), reduced %Wake after sleep onset, increased deep sleep (N3 / N4) time, increased % of time spent in deep sleep (N3 / N4), increased time in REM sleep, increased % of time spent in REM sleep, increased time in light sleep (N1 / N2), increased % of time spent in light sleep (N1 / N2), increased sleep efficiency, increased sleep maintenance, reduced number of awakenings during sleep, reduced time to fall asleep, increased feeling of rest, increased feeling of refreshment upon and / or after awakening, increased feeling of recovery, increased feeling of being ready for the day's activities, reduced daytime sleepiness or combinations thereof, preferably the sleep effect is biomeasured or biosensed. 10. The fragrance composition according to embodiment 1, wherein the fragrance ingredient is a pure fragrance (i.e. a non-encapsulated fragrance), an encapsulated fragrance or a combination thereof, preferably the encapsulated fragrance is encapsulated by microcapsules having a biodegradability of at least 60% by weight within 60 days according to OECD 301F. 11.ALDEHYDE C 10 DECYLIC;ALDEHYDE C 11 UNDECYLENIC;ALDEHYDE C 110 UNDECYLIC;ALDEHYDE C 12 LAURIC;ALDEHYDE C 12 MNA PURE;ALDEHYDE C 8 OCTYLIC FOOD GRADE;ALDEHYDE C 9 ISONONYLIC;ALDEHYDE C 9 NONYLIC FOOD GRADE;ALDEHYDE C 90 NONENYLIC 1% / TEC;ALDEHYDE C12(DODECANAL);ALDEHYDE ISO C 11;Mandarin aldehyde;trans-4-decenal, DECENAL-4-TRANS 10% / TEC;DIHYDROFARNESAL;Dodecanal;MYRALDENE;TANGERINOL;AMBERKETAL IPM;AMBERMAX;AMBROCENIDE;AMBROFIX;AMBROFIX FLAKES;BELAMBRÉ;BOISAMBRENE FORTE;CEDRYL ACETATE LIQUID;CEDRYL METHYL ETHER;CETALOX;ISO E SUPER;KARANAL;KEPHALIS;TIMBEROL;TRIMOFIX O;ANIMALIS 1745 SUBST.PMF 2;JUMP OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES, REPLACEMENTS;GUAIACOL;INDOFLOR;INDOLE;INDOLENE;ANETHOLE;ANISE STAR OIL;ANISIC ALDEHYDE;ANISYL ACETATE;DIHYDRO ANETHOLE;ESTRAGOLE;FENNEL OIL, ESSENTIAL OIL, EXTRACTS, BASES, SUBSTITUTES OR REPLACEMENTS;FENNEL SWEET DQ(AC)N 41632TT;FENNEL OIL SWEET;AND FENNEL OIL SWEET TECH;BENZYL ALCOHOL;BENZYL CINNAMATE;BOYS OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES;OLIBANUM OIL SOMALIA ORPUR;PHENYL ETHYL PHENYL ACETATE;ARTEMIA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES;CAMPER AND CAMPER OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;EUCALYPTOL AND EUCALYPTOL OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;LAVANDIN OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;LAVANDER OIL, EXTRACTS, ESSENTIAL OIL, SUBSTITUTES OR REPLACEMENTS;ROSEMARY OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;AND HIBA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;ACETAL CD;AMYL CINNAMIC ALDEHYDE;AMYL SALICYLATE;AURANTIOL PURE BENZYL ACETATE;BENZYL SALICYLATE;BOURGEONAL;CITRONELLOL;CITRONELLYL ACETATE;CRESYL METHYL ETHER PARA;CYCLAMEN ALDEHYDE EXTRA;CYCLOHEXAL;CYCLOHEXYL SALICYLATE;DIMETHYL ANTHRANILATE;DIMETHYL GERANIOL ALDEHYDE;HEXYL CINNAMIC ALDEHYDE DQ AC FORTE;LILIAL AND LILIAL SUBSTITUTES;LINALOOL;MEFROSOL;METHYL ANTHRANILATE;METHYL ANTHRANILATE EXTRA;METHYL BENZOATE;METHYL PHENYL ACETATE;NEROLI OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;NEROLINE CRYSTALS;NEROLIONE;ORANGE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;ORANGER CRYSTALS;ORANGER FLEUR CREME 1103 / 20;PELARGOL;PEONILE;PETALIA;PHENYL ETHYL ACETATE;PHENYL ETHYL ALCOHOL;PHENYL ETHYL ISOVALERATE;PHENYL ETHYL SALICYLATE ROSACETOL;ROSALVA CYCLOHEXYL PROPIONATE;ALLYL OENANTHATE;AMYL BUTYRATE;APHERMATE;APHERMATE;APHERMATE;BANANA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;BENZYL BUTYRATE;BENZYL ISOBUTYRATE;BENZYL PROPIONATE;BUTYL ACETATE;BUTYRIC ACID;BLACKCURSTEN OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;COGNAC WHITE OIL EXTRA DQ(AC)41547TT;CYCLOGALBANATE;DAMASCENONE;DAMASCONE ALPHA;DAMASCONE BETA;DAMASCONE DELTA;DECALACTONE DELTA;DECALACTONE GAMMA;DEWFRUIT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;DIETHYL MALONATE;DIMETHYL BENZYL CARBINYL ACETATE;DIMETHYL BENZYL CARBINYL BUTYRATE;DODECALACTONE DELTA;DODECALACTONE GAMMA;ETHYL ACETOACETATE;ETHYL BUTYRATE;ETHYL CAPROATE;ETHYL CAPRYLATE;ETHYL ISOAMYL KETONE;ETHYL ISOBUTYRATE;ETHYL METHYL-2-BUTYRATE;ETHYL OENANTHATE;ETHYL PELARGONATE;ETHYL PROPIONATE;ETHYL SAFRANATE;FLOROCYCLENE;FRAISTONE;FRUCTONE;FRUITATE;GARDOCYCLENE;GIVESCONE;Guava oil, essential oil, extract, substitute or substitute;HEXENYL-3-CIS BUTYRATE;HEXENYL-3-CIS ISOBUTYRATE;HEXYL BUTYRATE;HEXYL ISOBUTYRATE;ISOAMYL ACETATE EXTRA;ISOAMYL BUTYRATE FR;JASMACYCLENE;MANZANATE;Melon oil, essential oil, extract, substitute or alternative;METHOXY PHENYL BUTANONE;METHYL HEPTENONE PURE;METHYL HEXYL KETONE;METHYL-2-PENTENOIC ACID;2-NECTARYL;OCTALACTONE GAMMA;PEACH PURE;PHENOXY ETHYL ISOBUTYRATE;PHENYL ETHYL ISOBUTYRATE;PRUNOLIDE;RASPBERRY KETONE(N 112);AND STRAWBERRY PURE;AMYL VINYL CARBINOL;OCIMENE;ACETOIN;ACETYLPYRAZINE;BENZALDEHYDE;BUTYL BUTYRO LACTATE;CHOCOLATE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CORYLONE DRIED;CYCLOTENE;ETHYL MALTOL;HOMOFURONOL;HYDROXYETHYL METHYL THIAZOLE;ISOBUTAVAN;AND MALTYL ISOBUTYRATE;ACETAL E;ALCOHOL C 6 HEXYLIC;ALDEHYDE C 6 HEXYLIC FOOD GRADE;BUTYL QUINOLINE SECONDARY;CYCLAL C;DIPHENYL OXIDE;ELINTAAL;ETHYL DECADIENOATE;ETHYL DIMETHYLPYRAZINE;GALVANONE;GARDENOL;trans-2-HEXENAL;HEXENOL-2-TRANS;HEXENOL-3-CIS;HEXENYL-3-CIS ACETATE;HEXENYL-3-CIS BENZOATE;HEXENYL-3-CIS PROPIONATE;ISOCYCLOCITRAL;ISOHEXYL METHOXYPYRAZINE;LIFFAROME;LIGANTRAAL;MACEAL;METHYL OCTYNE CARBONATE;NEOFOLIONE;NONADIENOL-2,6;cis-6-NONENAL;NONENOL-6-CIS;PETITGRAIN OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;PHENOXYACETALDEHYDE;PYRALONE;RESEDAL;ROSE OXIDE;ROSYRANE SUPER;STEMONE;TRICYCLAL;TRIFERNAL;UNDECATRIENE;UNDECAVERTOL;VIOLET NITRILE;VIRIDINE;BASIL OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CAMOMILE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CITRONELLAL;SALVIA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CYPRISATE;EUCALYPTUS OIL, EXTRACTS, ESSENTIAL OIL, SUBSTITUTES OR REPLACEMENTS;HERBOXANE;PINOACETALDEHYDE;TANAISONE;THYMOL CRYSTALS;ADOXAL;AZULONE;CALONE 1951;FENNALDEHYDE;FLORALOZONE;FLORHYDRAL;MELONAL;SCENTENAL;TROPIONAL;AND VERNALDEHYDE;BUTU LEAF OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CARVONE LAEVO;CORN MINT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;FRESKOMENTHE;ISOMENTHONE DL;MENTHOL LAEVO;MENTHOL-DL;MENTHONE;MENTHYL ACETATE;PEPTA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;AND SPEARMINT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;AMBRETTOLIDE;CASHMERAN;COSMONE;CYCLOPENTADECANOLIDE;ETHYLENE BRASSYLATE;GALAXOLIDE;GALAXOLIDE S;HABANOLIDE;MUSCENONE;MUSK C14;SERENOLIDE;SILVANONE SUPRA;SYLKOLIDE;VELVIONE;CETONE V;DIHYDRO IONONE BETA;IONONE BETA;IRISONE ALPHA;IRISONE PURE;ISORALDEINE 70;ISORALDEINE 95;ORIVONE;ANGELIC;COAL CARCIS;COAL PAMPLE MOUSSE;DIMETHYL SULFIDE;GARDAMIDE;LAVIENOXIM;MERCA; BUTANE;METHYL ISOPROPYL THIAZOLE;NARDOSTE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;NEOCASPIRENE EXTRA;NONIVAMIDE 1% TRIACETIN;OXANE;PARADISAMIDE;PARAMENTONE;ACETOPHENONE;AUBEPINE PARA CRESOL;BICYCLO NONALACTONE;COUMARIN;ETHYL LIGHTONE;ETHYL VANILLIN;HELIOTROPIN;VANILLA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;VANILLIN;VANILLIN OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;VERATRIC ALDEHYDE;BORNEOL;BORNYL ACETATE LIQUID;BUTYL CYCLOHEXANOL PARA;BUTYL CYCLOHEXYL ACETATE PARA;JUNIOR PINK OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;CONIFERAN;EBANOL;EVERNYL;FENCHYL ACETATE;GUAIAC WOOD OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;ISONONANYL ACETATE;JAVANOL;KOHINOOL;MENTHANYL ACETATE;METHYL CEDRYL KETONE;NOPYL ACETATE;OSYROL;OXYOCTALINE FORMATE;PATCHOULI OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;PINENE ALPHA;PINENE BETA;RADJANOL;RADJANOL SUPER;TURBINE, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;VERTOFIX COEUR;AND VETIVER OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;ALDEHYDE C12;AND MENTHYL 2. The fragrance composition of embodiment 1, further comprising at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 additional fragrance ingredients selected from the group consisting of: ACETATES. 12. The fragrance composition of embodiment 1, which is substantially free or essentially free of one or more macrocyclic musk compounds. 13. A consumer product comprising the fragrance composition according to embodiment 1, the consumer product being an air care product, a home care product, a personal care product, a hygiene product, a pet care product, a sanitary product, a fine fragrance, a hair care product or a beauty care product. 14. A method for enhancing at least one sleep benefit in a subject, comprising providing a fragrance composition according to embodiment 1 or a consumer product according to embodiment 13 to the subject in an amount effective to enhance at least one sleep benefit, preferably wherein the fragrance composition or consumer product is (i) sprayed or applied to the subject; (ii) sprayed or applied to furniture upholstery or fabrics, preferably bedding, laundry, blankets or pillowcases; and / or (iii) dispersed or diffused in the air. 15. The method of embodiment 14, wherein the at least one sleep effect is selected from the group consisting of improved sleep quality, increased total sleep time, reduced awakening after sleep onset (WASO), reduced %Wake after sleep onset, increased deep sleep (N3 / N4) time, increased % of time spent in deep sleep (N3 / N4), increased REM sleep time, increased % of time spent in REM sleep, increased light sleep (N1 / N2) time, increased % of time spent in light sleep (N1 / N2), increased sleep efficiency, increased sleep maintenance, reduced number of sleep awakenings, reduced time to fall asleep, increased feeling of rest, increased feeling of refreshment upon and / or after awakening, increased feeling of recovery, increased feeling of being ready for the day's activities, reduced daytime sleepiness, or a combination thereof, preferably the sleep effect is biomeasured or biosensed. EXAMPLES

[0133] The following examples are provided to further illustrate the present invention and should not be construed as limiting thereof, since many variations of the invention are possible without departing from its spirit or scope.

[0134] Example 1: Preparation of fragrance compositions and unscented control compositions

[0135] Perfume Examples 1 and 2, shown in Tables 1 and 2 below, respectively, are non-limiting examples of perfume composition formulations according to the present disclosure. Unscented Example 1, shown in Table 3, is a control outside the scope of the present disclosure. The perfume formulations shown below are made by mixing the listed ingredients in the listed ratios at room temperature.

[0136] [Table 1]

[0137] [Table 2]

[0138] [Table 3]

[0139] The fragrance examples were administered to the participants by applying a pillow spray. The pillow spray applications were formulated as described in Table 4. To make the pillow spray applications, each fragrance composition (Fragrance Example 1 or Example 2) was first mixed with isopropyl myristate (IPM) and then mixed with PEG-4 hydrogenated castor oil according to the ratios specified in Table 4. The remaining ingredients were then added to make the final formulation. For the fragrance samples, each subject was given 20 mL of the formulation in a 2 oz. white HDPE plastic bottle (supplied by Brad Pak Enterprises, Garwood, NJ) with a fine mist spray cap. Subjects also received an unscented sample in a similar bottle. Both samples were blind coded for testing.

[0140] [Table 4]

[0141] All fragrance compositions used in the study were reviewed by the IFF's Global Regulatory Affairs (GRA) and approved as safe for use in human subjects at the specific dose of 0.5% in pillow mist applications.

[0142] Example 2: Improvement of sleep using a fragrance composition

[0143] The purpose of this example is to demonstrate the sleep benefits of using the fragrance composition of the present disclosure. Two sleep studies were conducted. Study participants were 18-60 years old, generally healthy, self-reported mild sleep difficulties due to lifestyle factors, but had no clinical records of sleep disorders. Additionally, participants did not have irregular sleep patterns or schedules. Study 1 (using fragrance example 1) included 51 participants, including 27 women and 24 men, ages 22-55. Study 2 (using fragrance example 2) included 52 participants, including 29 women and 23 men, ages 20-57. Participants did not take any type of sleep aid or medication that would affect sleep during the study period and for three weeks prior to the start of the study. The study was conducted in the participants' own bedrooms, and participants were encouraged to maintain their habitual sleep schedule throughout the study period. All participants provided fully informed consent prior to participation, and all study procedures, including participant recruitment, were reviewed and approved by the Western Institutional Review Board (WIRB).

[0144] All participants were provided with a SleepScore™ Max device (SleepScore Labs, Carlsbad, California) along with setup instructions and anonymized user account. All participants were asked to download the SleepScore™ Max application from the Apple® Application Store onto their smartphone and then pair the SleepScore™ Max application with the SleepScore™ Max device. Once paired, the device was placed 1.3 to 3.9 feet (i.e., arm's length) away from the participant. The bottom of the device should be just above the top surface of the mattress, with nothing between the device and the participant. To ensure minimal interference, no objects with moving parts (e.g., electric fans) were placed near the device. The bedroom was maintained at room temperature (i.e., 25-28°C) and relative humidity of 38-85%. The SleepScore™ Max device was used to monitor the participants' sleep behavior. Nightly summary data from the system was downloaded using the SleepScore™ data visualization platform.

[0145] The study design is shown in Figure 1. An acclimation period of 3 nights / days was conducted at the beginning of the study to acclimate participants to the fragrance examples, unscented control, and application regime. Each study began on a given Monday of the week and ran for a total of 3 weeks, which was divided into three periods: (i) baseline period ("BL"; week 1); (ii) product use period 1 ("PUP1"; week 2); and (iii) product use period 2 ("PUP2"; week 3). The order in which the unscented control and scented samples were presented was counterbalanced across participants.

[0146] On a given night during the study, participants were asked to spray the entire pillowcase with the spray three times just before bedtime and to complete the questionnaire shown in FIG. 2. Before lights out, participants were asked to start sleep tracking via the SleepScore™ Max application on their smartphone. Participants were asked to stop sleep tracking immediately after getting out of bed in the morning. Participants were also asked to complete the morning questionnaire shown in FIG. 3 after fully waking up and before starting their morning routine. All questionnaires were completed electronically via web-based data collection software (Compusense®). The deadline for completing the pre-bedtime questionnaire was set at 2:00 a.m., and the deadline for completing the morning questionnaire was set at 12:00 noon, after which participants were not allowed to complete the questionnaire. Participants were not allowed to view previous days' responses when completing the questionnaire. Additionally, participants were asked to complete the questionnaire based on their own sleep experience without reference to the sleep measurements displayed in the SleepScore™ Max application. Participants were also asked to complete the Product Use Questionnaire, shown in Figures 4A and 4B. The Product Use Questionnaire explored participants' experiences with products they had used the previous night.

[0147] Continuing with reference to FIG. 1, during the BL period, participants were asked to track their sleep using a SleepScore™ Max device and to complete questionnaires before bedtime and in the morning. During PUP1 and PUP2 periods, participants were asked to track their sleep using a SleepScore™ Max device and to complete questionnaires before bedtime and in the morning. Participants were also asked to use control example 1 or fragrance examples 1 and / or 2 according to the instructions in FIG. 1. The first three nights (Friday-Sunday) were considered as acclimation nights. The PUP period lasted from Friday night to Tuesday night of the following week. The study was conducted in a blinded manner so that participants did not know whether they were receiving the control example or the fragrance example.

[0148] Prior to statistical analysis, the study results were processed to remove outliers. All data from the habituation night were excluded from statistical analysis. Nightly objective sleep data as well as self-reports before bedtime and in the morning were analyzed in R (version 4.1) using multilevel regression analysis to account for the nested structure of the data (night per subject). One-sided tests were performed at the α=0.05 level. The following regression model: Sleep parameters ij = constant 0i +β×Test period ij A log-based regression was used to code observations during control or baseline use as 0 and observations during nights during active scent use as 1. Both self-reported and objective data were analyzed for participants' reports of their sleep and previous night's use, which were tracked during the scent example and control use periods with full adherence to the instructions given, including within-subject comparisons by night or day. Secondary analyses were also performed using the same methodology, except that BL was used as the control condition. When distributions of sleep onset latency (SOL) and / or wake after sleep onset (WASO) quantities were skewed and did not meet the normality assumptions required for statistical tests, log-transformations were performed prior to analysis.

[0149] Table 5 summarizes the biometric parameters measured using the SleepScore™ Max device for Study 1. The results show that participants exposed to Fragrance Example 1 of the present disclosure had improved sleep quantity and / or quality compared to Control Example 1. Similar results were observed for self-reported indicators (data not shown).

[0150] [Table 5]

[0151] The results shown in Table 5 indicate that exposure to Fragrance Example 1 has a beneficial effect on sleep. When exposed to Fragrance Example 1, participants fell asleep in less time (-2.7 minutes, -19%, p<0.01) and experienced fewer nighttime awakenings (-4.9 minutes, 19%, p<0.05) compared to Control Example 1. This resulted in improved sleep efficiency (+1.8%, p<0.01) and sleep maintenance (+1.1%, p<0.05). There was also an increase in the amount of time participants spent in deep sleep, both absolute (+4.9 minutes, +6%, p<0.05) and relative (+1.5%, p<0.05%). This resulted in an overall improvement in sleep scores (+2, +3%, p<0.05) and physical scores (+1.8, +2%, p<0.05) observed using Fragrance Example 1 compared to Control Example 1.

[0152] Table 6 summarizes the biometric parameters measured using the SleepScore™ Max device in Study 2. Table 7 summarizes the self-reported measures in Study 2. The results show that participants exposed to Fragrance Example 2 of the present disclosure had improved sleep quantity and quality compared to Control Example 1.

[0153] [Table 6]

[0154] [Table 7]

[0155] The results, shown in Table 6, indicate that exposure to Fragrance Example 2 had a beneficial effect on sleep. Participants fell asleep in less time (-2.4 minutes, -15%, p<0.05). As a result, participants exposed to Fragrance Example 2 reported an overall improvement in sleep quality (+0.3, +4%, p<0.05) as well as feeling more rested (+0.3, +4%, p<0.01) and more refreshed in the morning (+0.2, +4%, p<0.05) compared to Control Example 1.

[0156] Example 3: Sleep Improvement with Exemplary Fragrance Compositions

[0157] The impact of a third exemplary fragrance, Fragrance Example 3 (see Table 8, formulated as described in Example 1), on sleep was evaluated according to the methods described in Examples 1 and 2. A dose of Fragrance Example 3 was tested in a pillow spray at half the dose used to test Fragrance Examples 1 and 2 (see Example 1) and compared to an unscented control pillow spray (Unscented Example 2, see Table 10). The study enrolled 51 participants, including 32 women and 19 men, ages 20-60.

[0158] [Table 8]

[0159] [Table 9]

[0160] [Table 10]

[0161] Table 11 summarizes the biometric parameters measured in this study using the SleepScore™ Max device. The results shown in Table 11 indicate that lower doses of the exemplary compounds described herein, such as those in Examples 1 and 2, may also beneficially affect sleep.

[0162] [Table 11]

[0163] Exposure to fragrance example 3 improved the physical score compared to unscented example 2 (+1.8, +2%, p<0.05). This suggests that participants' deep sleep time increased. Table 11 shows that participants' deep sleep time showed an increasing trend.

[0164] Fragrance Example 2 (see Table 2) was also tested according to the method described in Example 2 at 0.11% by weight pillow spray (half the dose tested in Examples 1 and 2; see Table 4) and compared to Control Example 1. The study enrolled 32 participants, including 24 women and 8 men, ages 23-60. The results are shown in Table 12.

[0165] [Table 12]

[0166] As shown in Table 12, even low doses of Fragrance Example 2 (compared to the doses tested in Examples 1 and 2) were found to improve sleep efficacy, increasing REM sleep time, sleep efficiency, and sleep maintenance. Increased sleep scores and mental scores demonstrated an overall improvement in sleep quality. Consistent with the objective measures, participants also reported fewer interruptions, improved sleep quality, and a sense of refreshment even at lower doses of Fragrance Example 2 (p<0.05 for all self-report measures).

[0167] These data demonstrate that combinations of the exemplary compounds described herein improve sleep over a wide range of concentrations.

[0168] Example 4: Robustness of sleep-improving compositions

[0169] The ability of a fragrance composition for improving sleep to maintain its sleep-improving effect when formulated with additional ingredients that do not have a sleep benefit was evaluated.

[0170] First, an existing exemplary finished fragrance (EFF1) containing 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline was tested according to the method of Example 2 to determine whether it had any effect on sleep. EFF1 was formulated into a pillow spray as shown in Table 13. This resulted in a concentration of 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline in the pillow spray of 0.00475% by weight. The study included 54 participants, including 27 women and 27 men, ages 21-60.

[0171] [Table 13]

[0172] Table 14 summarizes the parameters for EFF1 and Control 1 that were biomeasured using the SleepScore™ Max device.

[0173] [Table 14]

[0174] The results shown in Table 14 indicate that EFF1 does not have a beneficial effect on sleep. Next, the effect on sleep when EFF1 is combined with Fragrance Example 1 was evaluated.

[0175] Perfume Example 1 described in Example 1 (see Table 1) was formulated into a pillow spray with EFF1 as shown in Table 15 to form a mixed composition (MXC).

[0176] [Table 15]

[0177] The sleep study was performed similarly to that described in Example 2. The study included 31 participants (2 men and 29 women) aged 18-60 years who self-reported mild sleep difficulties due to lifestyle factors but had no clinical records of sleep disorders. Participants had a normal sense of smell, no allergies, and were not taking medications that affected sleep. Additionally, participants did not have irregular sleep patterns or schedules. Participants did not take any type of sleep aid or medication that affected sleep during the study period or for 3 weeks prior to the start of the study.

[0178] The study design is shown in Figure 5. An acclimation period of 3 nights / days was conducted at the beginning of the study to acclimate participants to MXC or unscented control (Control 1) and application regime. The study was conducted over a 2-week period, with the first 3 days of each week being used for acclimation to MXC or Control 1. Sleep measurements were conducted over the last 4 days of each week. The order of presentation of unscented control and MXC samples was counterbalanced across participants.

[0179] Table 16 summarizes the parameters for MXC and Control 1 as biomeasured using the SleepScore™ Max device.

[0180] [Table 16]

[0181] As shown in Table 16, the addition of Fragrance Example 1 to EFF1 improved a wide range of sleep parameters, including increased total sleep time and REM sleep time. Increased sleep and mental scores demonstrated an overall improvement in sleep quality. Consistent with the objective measures, participants self-reported fewer nighttime interruptions (-0.3, -18%, p<0.05) and longer sleep times (+16.8 min, +4.2%, p<0.01).

[0182] These data indicate that fragrances with sleep-improving properties remain robust when combined with fragrances that do not have sleep-improving properties. Thus, the compounds and compositions described herein can be combined with ingredients that do not exhibit sleep-improving properties to produce fragrance compositions for sleep improvement.

[0183] It is to be understood that every maximum numerical limitation given throughout this specification includes every lower numerical limitation, as if such lower numerical limitation were expressly written herein. Every minimum numerical limitation given throughout this specification will include every higher numerical limitation, as if such higher numerical limitation were expressly written herein. Every numerical range given throughout this specification will include every narrower numerical range that is included within such broader numerical range, as if such narrower numerical value were written herein.

[0184] The dimensions and values ​​disclosed herein should not be understood to be strictly limited to the exact numerical values ​​recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value. For example, a value disclosed as "40 mm" is intended to mean "about 40 mm."

[0185] All documents cited herein, including cross-referenced or related patents or applications and patent applications or patents to which this application claims priority or benefit, are incorporated herein by reference in their entirety, unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to the invention disclosed or claimed herein, or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses such invention. Furthermore, to the extent that any meaning or definition of a term in this specification conflicts with a meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this specification shall control.

[0186] While particular embodiments of the present disclosure have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the present disclosure. It is therefore intended in the appended claims to cover all such changes and modifications that are within the scope of this disclosure.

Claims

1. Skeletal structure of formula (I): 【Chemistry 1】 (In the formula, each open position of said backbone structure is independently optionally substituted; 【Chemistry 2】 is a single or double bond; and The six-membered ring of formula (I) contains 0 to 3 double bonds. A fragrance composition for improving sleep, comprising one or more compounds comprising the backbone structure of formula (I), wherein the one or more compounds comprising the backbone structure of formula (I) are present in a total concentration of greater than 0.05% by weight of the total weight of the composition.

2. The skeleton structure of the formula (I) is 【Chemistry 3】 The fragrance composition of claim 1 having the structure:

3. 3. The fragrance composition according to claim 1 or 2, wherein at least one of said one or more compounds comprising the skeletal structure of formula (I) is a heteroatom musk compound.

4. The fragrance composition according to any one of claims 1 to 3, comprising at least 2, 3, 4 or 5 compounds comprising the skeletal structure of formula (I), optionally at least 3 compounds comprising the skeletal structure of formula (I).

5. 5. The fragrance composition according to claim 1, comprising the one or more compounds comprising the skeletal structure of formula (I) in a total concentration ranging from about 0.1% by weight to about 100% by weight of the total weight of the composition.

6. 1. A fragrance composition for improving sleep comprising one or more heteroatomic musk compounds, wherein said one or more heteroatomic musk compounds are present in a total concentration greater than 0.05% by weight of the total weight of said composition.

7. At least one of the one or more heteroatom musk compounds has a skeletal structure of formula (I): 【Chemistry 4】 (In the formula, each open position of said backbone structure is independently optionally substituted; 【Chemistry 5】 is a single or double bond; and The six-membered ring of formula (I) contains 0 to 3 double bonds. The fragrance composition of claim 6, comprising:

8. 8. The fragrance composition according to claim 6 or 7, wherein at least 2, 3, 4 or 5 of said one or more heteroatomic musk compounds comprise the skeletal structure of formula (I), optionally at least 3 heteroatomic musk compounds comprise the skeletal structure of formula (I).

9. 9. The fragrance composition according to any one of claims 6 to 8, comprising one or more heteroatomic musk compounds in a total concentration ranging from about 0.1% to about 100% by weight of the total weight of the composition.

10. 10. The fragrance composition according to claim 1, further comprising at least one acyclic musk compound.

11. 11. The fragrance composition of claim 10, wherein said at least one acyclic musk compound is present in a total concentration of at least 0.0025% by weight of the total weight of the composition.

12. 12. The fragrance composition according to claim 10 or 11, wherein the weight ratio of said one or more heteroatomic musk compounds or said one or more compounds comprising the skeletal structure of formula (I) to said at least one acyclic musk compound is from about 55:1 to 45:1 or from 52:1 to 47:

1.

13. The one or more compounds comprising the backbone structure of formula (I) include: 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-Pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 4,6,6,7,8,8-Hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene; 13. The fragrance composition of any one of claims 1 to 5 or 10 to 12, which is 2,2,6,6,7,8,8-heptamethyldecahydro-2H-indeno[4,5-b]furan; 2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan; or one or more stereoisomers of any of the foregoing.

14. The one or more heteroatom musk compounds may be selected from the group consisting of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 7,7,8,9,9-Pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline; 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 4,6,6,7,8,8-Hexamethyl-1,3,4,6,7,8-hexahydrocyclopenta[g]isochromene; 13. The fragrance composition of any one of claims 6 to 12, which is 2,2,6,6,7,8,8-heptamethyldecahydro-2H-indeno[4,5-b]furan; 2,6,6,7,8,8-hexamethyldecahydro-2H-indeno[4,5-b]furan; or one or more stereoisomers of any of the foregoing.

15. 15. The fragrance composition of any one of claims 10 to 14, wherein the at least one acyclic musk compound is 1-propanol, 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methyl-, 1-propanoate; 1-(3,3-dimethylcyclohexyl)ethyl acetate; 2-(1-(3,3-dimethylcyclohexyl)ethoxy)-2-oxoethylpropionate; 2-(1-(3,3-dimethylcyclohexyl)ethoxy)-2-methylpropyl cyclopropanecarboxylate; 2-((3,5-dimethylhex-3-en-2-yl)oxy)-2-methylpropyl cyclopropanecarboxylate; or any combination thereof.

16. The fragrance composition according to any one of claims 1 to 15, further comprising a solvent selected from dipropylene glycol (DPG), isopropyl myristate, ethanol, triethyl citrate, or any combination thereof.

17. 17. The fragrance composition according to any one of claims 1 to 5 or 10 to 16, wherein the one or more compounds comprising the backbone structure of formula (I) are pure fragrances, encapsulated, or a combination thereof.

18. 18. The fragrance composition according to any one of claims 6 to 17, wherein said one or more heteroatom musk compounds are pure fragrance, encapsulated, or a combination thereof.

19. 19. The fragrance composition according to any one of claims 10 to 18, wherein said at least one acyclic musk compound is a pure fragrance, is encapsulated, or a combination thereof.

20. (i) at least three heteroatom musk compounds; (ii) at least one acyclic musk compound, 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline or 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; and optionally a solvent selected from dipropylene glycol (DPG), isopropyl myristate, ethanol, triethyl citrate, or any combination thereof.

21. 21. The fragrance composition of claim 20, wherein the weight ratio of (i) to (ii) is from 55:1 to 45:1 or from 52:1 to 47:

1.

22. (i) 95% to 99% by weight of said heteroatomic musk compound; (ii) 1% to 5% by weight of the acyclic musk compound, 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline or 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole; 22. The fragrance composition according to claim 20 or 21, comprising:

23. 23. The fragrance composition according to any one of claims 20 to 22, wherein the heteroatom musk compounds are indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline.

24. comprising the heteroatom musk compound and the acyclic musk compound, (i) the heteroatom musk compounds are indeno[4,5-d]-1,3-dioxin, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and (ii) The fragrance composition according to any one of claims 20 to 23, wherein the acyclic musk compound is 1-propanol, 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methyl-, 1-propanoate.

25. 25. The fragrance composition of claim 24, comprising: 40% to 45% by weight of indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 5% to 15% by weight of 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 40% to 45% by weight of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and 0.1% to 5% by weight of 1-propanol, 2-[1-(3,3-dimethylcyclohexyl)ethoxy]-2-methyl-, 1-propanoate, the weight percentages being based on the total weight of the composition.

26. 24. The fragrance composition according to claim 20, comprising the heteroatom musk compound and 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline, wherein the heteroatom musk compound is indeno[4,5-d]-1,3-dioxine, 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline.

27. 27. The fragrance composition according to claim 26, comprising: 40% to 45% by weight of indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 5% to 15% by weight of 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 40% to 45% by weight of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and 0.1% to 5% by weight of 7,7,8,9,9-pentamethyl-6,7,8,9-tetrahydro-5H-cyclopenta[h]quinazoline.

28. 24. The fragrance composition according to any one of claims 20 to 23, comprising said heteroatom musk compound and 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole, said heteroatom musk compound being indeno[4,5-d]-1,3-dioxine; 4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; and 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline.

29. 29. The fragrance composition according to claim 28, comprising: 40% to 45% by weight of indeno[4,5-d]-1,3-dioxine,4,4a,5,6,7,8,9,9b-octahydro-7,7,8,9,9-pentamethyl; 5% to 15% by weight of 1,1,2,3,3-pentamethyl-2,5,6,7-tetrahydroinden-4-one; 40% to 45% by weight of 7,7,8,9,9-pentamethyl-6,6a,7,8,9,9a-hexahydro-5H-cyclopenta[h]quinazoline; and 0.1% to 5% by weight of 2,2,6,6,7,8,8-heptamethyl-3a,5,6,7,8,8b-hexahydro-4H-indeno[4,5-d][1,3]dioxole.

30. 30. The fragrance composition according to any one of claims 20 to 29, wherein said fragrance ingredient is a pure fragrance, an encapsulated fragrance or a combination thereof, preferably said encapsulated fragrance is encapsulated by microcapsules having a biodegradability of at least 60% by weight within 60 days according to OECD 301F.

31. 31. The fragrance composition according to claim 1, wherein the sleep improvement comprises at least one or more sleep benefits selected from the list comprising improved sleep quality, increased total sleep time, reduced awakening after sleep onset (WASO), reduced % Wake after sleep onset, increased deep sleep (N3 / N4) time, increased % of time spent in deep sleep (N3 / N4), increased time in REM sleep, increased % of time spent in REM sleep, increased time in light sleep (N1 / N2), increased % of time spent in light sleep (N1 / N2), increased sleep efficiency, increased sleep maintenance, reduced number of awakenings during sleep, reduced time to fall asleep, increased feeling of rest, increased feeling of refreshment upon and / or after awakening, increased feeling of recovery, increased feeling of being ready for the day's activities or reduced daytime sleepiness.

32. ALDEHYDE C 10 DECYLIC;ALDEHYDE C 11 UNDECYLENIC;ALDEHYDE C 110 UNDECYLIC;ALDEHYDE C 12 LAURIC;ALDEHYDE C 12 MNA PURE;ALDEHYDE C 8 OCTYLIC FOOD GRADE;ALDEHYDE C 9 ISONONYLIC;ALDEHYDE C 9 NONYLIC FOOD GRADE;ALDEHYDE C 90 NONENYLIC 1% / TEC;ALDEHYDE C12 (DODECANAL); ALDEHYDE ISO C 11; MANDARINAL; TRANS-4-DECENAL; DECENAL-4-TRANS 10% / TEC; DIHYDROFARNESAL; DODECANAL; MYRALDENE; TANGERINOL; AMBER KETAL; AMBERKETAL IPM; AMBERMAX; AMBROSENIDE; AMBROFIX; AMBROFIX FLAKES; BELAMBRÉ; BOISAMBRENE FORTE; CEDRYL ACETATE LIQUID; CEDRYL METHYL ETHER; CETALOX; ISO E SUPER; KARANAL; KEPHALIS; TIMBEROL; TRIMOFIX O; ANIMALIS 1745 SUBST. PMF 2; JUMPER OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES, SUBSTITUTES; GAUIACOL; INDOFLOR; INDOLE; INDOLENE; ANETHOLE; ANISE STAR OIL; ANISIC ALDEHYDE; ANISYL ACETATE; DIHYDRO ANETHOLE; ESTRAGOLE; FENNEL OIL, ESSENTIAL OIL, EXTRACTS, BASES, SUBSTITUTES OR ALTERNS; FENNEL SWEET DQ(AC)N 41632TT; FENNEL OIL SWEET; AND FENNEL OIL SWEET TECH; BENZYL OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR ALTERNS; BENZYL ALCOHOL; BENZYL CINNAMAT; BOYS OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; OLIBANUM OIL SOMALIA ORPUR; PHENYL ETHYL PHENYL ACETATE; MUGINOUS OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES;Camphor and camphor oil, essential oil, extract, substitute or substitute; EUCALYPTOL and eucalyptol oil, essential oil, extract, substitute or substitute; LAVANDIN OIL, essential oil, extract, substitute or substitute; LAVENDER OIL, extract, essential oil, substitute or substitute; ROSMARY OIL, essential oil, extract, substitute or substitute; AND HIBA OIL, essential oil, extract, substitute or substitute; ACETAL CD; AMYL CINNAMIC ALDEHYDE; AMYL SALICYLATE; AURANTIOL PURE BENZYL ACETATE; BENZYL SALICYLATE; BOURGEONAL; CITRONELLOL; CITRONELLYL ACETATE; CRESYL METHYL ETHER PARA; CYCLAMEN ALDEHYDE EXTRA; CYCLOHEXAL; CYCLOHEXYL SALICYLATE; DIMETHYL ANTHRANILATE; DIMETHYL PHENYL THYL CARBINOL; DUPICAL; ETHYL LINALOOOL; FLOROSA; FLOROSA HC; GERANIOL; Geranium oil, essential oil, extract, substitute or substitute; GERANODYLE; GERANYL ACETATE; GERANYL BUTYRATE;HEDIONE;HEDIONE HC;HEXENYL-3-CIS SALICYLATE;HEXYL CINNAMIC ALDEHYDE;HEXYL CINNAMIC ALDEHYDE DQ AC XI 41505TT;HEXYL SALICYLATE; HYDROXYCITRONELLAL; ISOBUTYL PHENYL ACETATE; ISOBUTYL SALICYLATE; JASMATONE; Jasmine oil, essential oil, extract, substitute or substitute; JASMONE CIS;JASMONYL;JASMOPYRANE FORTE; LILIAL and lilial substitutes; LINALOOL; MEFROSOL; METHYL ANTHRANILATE; METHYL ANTHRANILATE EXTRA; METHYL BENZOATE; METHYL PHENYL ACETATE; NEROLI OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS; NEROLINE CRYSTALS; NEROLIONE; ORANGE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS;ORANGER CRYSTALS;ORANGER FLEUR CREME 1103 / 20;PELARGOL;PEONILE;PETALIA;PHENYL ETHYL ACETATE;PHENYL ETHYL ALCOHOL; PHENYL ETHYL ISOVALERATE; PHENYL ETHYL SALICYLATE CRYSTALS; ROSACETOL; ROSALVA; rose oil, essential oil, extract, substitute or substitute; SUPER MUGUET;TERPINEOL PURE;TETRAHYDRO LINALOOL; VERDANTIOL; YARA YARA; YLANG OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; ACETATE C 6 HEXYLIC; AGRUMEX; ALLYL AMYL GLYCOLATE; ALLYL CAPROATE; ALLYL CYCLOHEXYL PROPIONATE; ALLYL OENANTHATE; AMYL BUTYRATE; APHERMATE; APPLE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; BANANA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; BENZYL BUTYRATE; BENZYL ISOBUTYRATE; BENZYL PROPIONATE; BUTYL ACETATE; BUTYRIC ACID; CROSSCURST OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS; COGNAC WHITE OIL EXTRA DQ(AC)41547TT; CYCLOGAL BANATE; DAMASCENONE; DAMASCONE ALPHA; DAMASCONE BETA; DAMASCONE DELTA; DECALACTONE DELTA; DECALACTONE GAMMA; DEWFRUIT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS; DIETHYL MALONATE; DIMETHYL BENZYL CARBINYL ACETATE; DIMETHYL BENZYL CARBINYL BUTYRATE; DODECALACTONE DELTA; DODECALACTONE GAMMA; ETHYL ACETOACETATE; ETHYL BUTYRATE; ETHYL CAPROATE; ETHYL CAPRYLATE; ETHYL ISOAMYL KETONE; ETHYL ISOBUTYRATE; ETHYL METHYL-2-BUTYRATE;ETHYL OENANTHATE; ETHYL PELARGONATE; ETHYL PROPIONATE; ETHYL SAFRANATE; FLOROCYCLENE; FRAISTONE; FRUCTONE; FRUITATE; GARDOCYCLENE; GIVESCONE; guava oil, essential oil, extract, substitute or alternative; BUTYRATE;HEXENYL-3-CIS ISOBUTYRATE;HEXYL BUTYRATE;HEXYL ISOBUTYRATE;ISOAMYL ACETATE EXTRA;ISOAMYL BUTYRATE FR; JASMACYCLENE; MANZANATE; melon oil, essential oil, extract, substitute or replacement; METHOXY PHENYL BUTANONE; METHYL HEPTENONE PURE; METHYL HEXYL KETONE;METHYL-2-PENTENOIC ACID;2-NECTARYL;OCTALACTONE GAMMA;PEACH PURE;PHENOXY ETHYL ISOBUTYRATE;PHENYL ETHYL ISOBUTYRATE;PRUNOLIDE;RASPBERRY KETONE(N 112); and STRAWBERRY PURE; AMYL VINYL CARBINOL; OCIMENE; ACETOIN; ACETYLPYRAZINE; BENZALDEHYDE; BUTYL BUTYRO LACTATE; CHOCOLATE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS; CORYLONE DRIED; CYCLOTENE; ETHYL MALTOL; HOMOFURONOL; HYDROXYETHYL METHYLTHIAZOLE; ISOBUTAVAN; and MALTYL ISOBUTYRATE; ACETAL E; ALCOHOL C 6 HEXYLIC; ALDEHYDE C 6 HEXYLIC FOOD GRADE; BUTYL QUINOLINE SECONDARY;CYCLAL C;DIPHENYL OXIDE;ELINTAAL;ETHYL DECADIENOATE;ETHYL DIMETHYLPYRAZINE;GALVANONE;GARDENOL;trans-2-HEXENAL;HEXENOL-2-TRANS;HEXENOL-3-CIS;HEXENYL-3-CIS ACETATE;hexenyl-3-cis benzoate; hexenyl-3-cis propionate; isocyclohexyl methoxypyrazine; liffarom; ligantral; maceal; methyl octyne carbonate; neofolio; nonadienal; nonadienol-2,6; cis-6-nonenal; nonenol-6-cis; petitgrain oil, essential oil, extract, substitute or replacement; phenoxyacetaldehyde; phenylacetaldehyde; pyralone; resedal; rose oxide; roseyran. SUPER; STEMONE; TRICYCLAL; TRIFERNAL; UNDECATRIENE; UNDECAVERTOL; VIOLET NITRILE; VIRIDINE; BASIL OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; CHAMOMILE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; CITRONELLAL; SALVIA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; CYPRISATE; EUCALYPTUS OIL, EXTRACTS, ESSENTIAL OIL, SUBSTITUTES OR SUBSTITUTES; HERBOXANE; PINOACETALDEHYDE; TANAISONE; THYMOL CRYSTALS; ADOXAL; AZULONE; CALONE 1951; FENNALDEHYDE; FLORALOZONE; FLORHYDRAL; MELONAL; SCENTENAL; TROPIONAL; and VERNALDEHYDE; BUTU LEAF OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; CARVONE LAEVO; CORN MINT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; FRESKOMENTH; ISOMENTHONE DL; MENTHOL LAEVO; MENTHOL-DL; MENTHONE; MENTHYL ACETATE; MENTHA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; AND SPEARMINT OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; AMBRETTOLIDE; CASHMERAN; COSMONE; CYCLOPENTADECANOLIDE; ETHYLENE BRASSYLATE; GALAXOLIDE; GALAXOLIDE S; HABANOLIDE; MUSCENONE; MUSK C14; SERENOLIDE; SILVANONE SUPRA; SYLKOLIDE; VELVIONE;CETONE V; DIHYDRO IONONE BETA; IONONE BETA; IRISON ALPHA; IRISON PURE; ISORALDEINE 70; ISORALDEINE 95; ORIVONE; ANGELIC; COAL CARCIS; COAL PAMPLE MOUSSE; DIMETHYLSULPHIDE; GARDAMIDE; LAVIENOXIM; MERCAPTA; METHYL ISOPROPYL THIAZOLE; NARDOSTE OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS; NEOCASPIRENE EXTRA; NONIVAMIDE 1% TRIACETIN; OXANE; PARADISAMIDE; PARAMENTHONE; ACETOPHENONE; AUBEPINE PARA CRESOL; BICYCLO NONALACTONE; COUMARIN; ETHYL LIGHTONE; ETHYL VANILLIN; HELIOTROPIN; VANILLA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS; VANILLIN; VANORIA OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR REPLACEMENTS; VERATRIC ALDEHYDE; BORNEOL; BORNYL ACETATE LIQUID; BUTYL CYCLOHEXANOL PARA; BUTYL CYCLOHEXYL ACETATE PARA; Juniperus officinalis oil, essential oil, extract, substitute or replacement; CONIFERAN; EBANOL; EVERNYL; FENCHYL ACETATE; GUAIAC WOOD OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; ISONONANYL ACETATE; JAVANOL; KOHINOL; MENTHANYL ACETATE; METHYL CEDRYL KETONE; NOPYL 32. The fragrance composition of any one of claims 1 to 31, further comprising at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9 or at least 10 additional fragrance ingredients selected from the group consisting of: METHYL ACETATE; OSYROL; OXYOCTALINE FORMATE; PATCHOULI OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; PINENE ALPHA; PINENE BETA; RADJANOL; RADJANOL SUPER; TURBINE, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; VERTOFIX COEUR; and VETIVER OIL, ESSENTIAL OIL, EXTRACTS, SUBSTITUTES OR SUBSTITUTES; ALDEHYDE C12; and MENTHYL ACETATE.

33. 33. The fragrance composition of any one of claims 1 to 32, which is substantially free or essentially free of one or more macrocyclic musk compounds.

34. 34. A consumer product comprising the fragrance composition according to any one of claims 1 to 33, the consumer product being an air care product, a home care product, a fabric care product, a personal care product, a hygiene product, a pet care product, a fine fragrance, a hair care product or a beauty care product.

35. 35. A method for improving at least one sleep effect in a subject, comprising providing to the subject a fragrance composition according to any one of claims 1 to 33 or a consumer product according to claim 34 in an amount effective to improve at least one sleep effect.

36. 36. The method of claim 35, wherein the at least one sleep effect is selected from the group consisting of improved sleep quality, increased total sleep time, reduced awakening after sleep onset (WASO), reduced % Wake after sleep onset, increased time in deep sleep (N3 / N4), increased % time spent in deep sleep (N3 / N4), increased time in REM sleep, increased % time spent in REM sleep, increased time in light sleep (N1 / N2), increased % time spent in light sleep (N1 / N2), increased sleep efficiency, increased sleep maintenance, reduced number of awakenings during sleep, reduced time to fall asleep, increased feeling of rest, increased feeling refreshed upon and / or after awakening, increased feeling of recovery, increased feeling of being ready for the day's activities, reduced daytime sleepiness, or any combination thereof.

Images